[10-Q] Aimfinity Investment Corp. I Quarterly Earnings Report

Rhea-AI Filing Summary

Aimfinity Investment Corp. I filed its 10-Q showing modest non-operating profits and significant balance sheet changes typical of a SPAC nearing its deadline. For the six months ended June 30, 2025, the company reported net income of $75,425, driven by $484,941 of interest on trust assets and $409,516 of formation and operating costs. For Q2, net income was $10,494.

Trust assets were $13,981,534 as of June 30, 2025, after the redemption of 1,996,522 Class A shares for $23,778,577. 1,116,476 ordinary shares were classified as redeemable at $12.52 each. Working capital showed a deficit of $2,515,028, and management disclosed “substantial doubt” about continuing as a going concern absent a business combination by the extended deadline.

The company continues to pursue its merger with Docter Inc. It converted $1,500,000 of sponsor loans into 150,000 private units on April 8, 2025, and restructured deferred IPO underwriting fees on June 13, 2025 to $80,000 cash plus 132,875 PubCo shares for each underwriter at closing. Extensions funded through deposits push the combination window to October 28, 2025.

Positive

• None.

Negative

• Going concern warning: management cites “substantial doubt” about the company’s ability to continue as a going concern without completing a business combination by the extended deadline.

Insights

SPAC and Capital Markets Analyst

Small H1 profit from trust interest; material going-concern risk remains.

Aimfinity posted $75,425 net income for H1 2025, largely from $484,941 of trust interest offset by $409,516 in operating costs. Redemptions removed $23,778,577 from the trust, leaving $13,981,534 as of June 30, 2025.

The filing notes a working capital deficit of $2,515,028 and “substantial doubt” about continuing as a going concern if no deal closes by the extended deadline. Loan conversions into 150,000 private units ($1.5M) and the underwriter fee modification ($80,000 cash plus 132,875 shares each at closing) frame expected capital structure at completion.

Actual impact hinges on consummating the Docter Inc. business combination by October 28, 2025. Further disclosures will clarify closing status, remaining trust balance, and any additional redemptions.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2025

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _________to __________

Commission File Number 001-41361

AIMFINITY INVESTMENT CORP. I

(Exact name of registrant as specified in its charter)

Cayman Islands		98-1641561
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification Number)

221 W 9th St, PMB 235

Wilmington, Delaware 19801

(Address of principal executive offices and zip code)

(425) 365-2933

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Units, consisting of one New Unit and one Class 1 redeemable warrant, each exercisable for one Class A ordinary share at an exercise price of $11.50		AIMUF		OTC Market Group, Inc.
New Units, consisting of one Class A ordinary share and one-half of one Class 2 redeemable warrant, each full exercisable for one Class A ordinary share at an exercise price of $11.50		AIMTF		OTC Market Group, Inc.
Class 1 redeemable warrants, each exercisable for one Class A ordinary share at an exercise price of $11.50		AIMWF		OTC Market Group, Inc.

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☒ No ☐

As of October 17, 2025, there were 1,758,476 of the registrant’s Class A ordinary shares, par value $0.0001 per share, including 1,072,957 Class A ordinary share tendered by public shareholders for redemption, and 2,012,500 of the registrant’s Class B ordinary shares, par value $0.0001 per share, issued and outstanding.

AIMFINITY INVESTMENT CORP. I

TABLE OF CONTENTS

PART I – FINANCIAL INFORMATION		1
Item 1. FINANCIAL STATEMENTS (UNAUDITED)		1
Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024 (Unaudited)		1
Consolidated Statements of Operations for the Three and Six Months ended June 30, 2025 and 2024 (Unaudited)		2
Consolidated Statements of Changes in Shareholder’s deficit for the Six Months ended June 30, 2025 and 2024 (Unaudited)		3
Consolidated Statements of Cash Flows for the Six Months ended June 30, 2025 and 2024 (Unaudited)		4
Notes to Unaudited Financial Statements		5
Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS		23
Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK		30
Item 4. CONTROLS AND PROCEDURES		30
PART II – OTHER INFORMATION		31
Item 1. LEGAL PROCEEDINGS		31
Item 1A. RISK FACTORS		31
Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS FROM REGISTERED SECURITIES		31
Item 3. DEFAULTS UPON SENIOR SECURITIES		32
Item 4. MINE SAFETY DISCLOSURES		32
Item 5. OTHER INFORMATION		32
Item 6. EXHIBITS		33
SIGNATURES		34

i

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

AIMFINITY INVESTMENT CORP. I

CONSOLIDATED BALANCE SHEETS

(Unaudited)

		JUNE 30, 2025				DECEMBER 31, 2024
Assets
Current assets:
Cash		$	4,895			$	4,895
Total current assets			4,895				4,895
Cash and investments held in Trust Account			13,981,534				36,940,228
Total Assets		$	13,986,429			$	36,945,123
Liabilities, Temporary Equity, and Shareholders’ Deficit
Current liabilities:
Accounts payable and accrued expenses		$	959,182			$	767,613
Working Capital Loan - related party			1,393,270				1,202,852
Extension Loan - related party			167,471				1,305,000
Total Current Liabilities			2,519,923				3,275,465
Deferred underwriters’ discount			2,817,500				2,817,500
Total Liabilities			5,337,423				6,092,965
Commitments and Contingencies (Note 10)
Ordinary shares subject to possible redemption, 1,116,476 and 3,112,998 shares at redemption value of $12.52 and $11.87 per share as of June 30, 2025 and December 31, 2024, respectively			13,981,534				36,940,228
Shareholders’ Deficit:
Preference shares, $0.0001 par value, 1,000,000 shares authorized, none issued and outstanding			-				-
Class A ordinary shares, $0.0001 par value, 200,000,000 shares authorized, 642,000 and 492,000 issued and outstanding (excluding 1,116,476 and 3,112,998 shares subject to possible redemption as of June 30, 2025 and December 31, 2024, respectively)			64				49
Class B ordinary shares, $0.0001 par value, 20,000,000 shares authorized, 2,012,500 shares issued and outstanding			201				201
Additional paid-in capital			1,499,985				-
Accumulated deficit			(6,832,778	)			(6,088,320	)
Total Shareholders’ Deficit			(5,332,528	)			(6,088,070	)
Total Liabilities, Temporary Equity and Shareholders’ Deficit		$	13,986,429			$	36,945,123

The accompanying notes are an integral part of these unaudited consolidated financial statements.

1

AIMFINITY INVESTMENT CORP. I

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

		For the Three Months Ended				For the Three Months Ended				For the Six Months Ended				For the Six Months Ended
		June 30, 2025				June 30, 2024				June 30, 2025				June 30, 2024
Formation and operating costs		$	132,265			$	131,696			$	409,516			$	261,216
Loss from Operations			(132,265	)			(131,696	)			(409,516	)			(261,216	)
Other income:
Interest earned on cash and investments held in Trust Account			142,759				570,206				484,941				1,138,590
Net Income		$	10,494			$	438,510			$	75,425			$	877,374
Basic and diluted weighted ordinary average shares outstanding,  subject to possible redemption			1,116,476				3,614,392				1,590,788				3,794,137
Basic and diluted net income  per ordinary shares subject to possible redemption		$	0.20			$	0.16			$	0.34			$	0.30
Basic and diluted weighted average ordinary shares outstanding			2,641,313				2,504,500				2,573,285				2,504,500
Basic and diluted net loss  per ordinary share attributable to Aimfinity Investment LLC		$	(0.08	)		$	(0.05	)		$	(0.18	)		$	(0.11	)

The accompanying notes are an integral part of these unaudited consolidated financial statements.

2

AIMFINITY INVESTMENT CORP. I

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ DEFICIT

(Unaudited)

		For the Six Months Ended June 30, 2025
		Preference shares								Ordinary Shares																Additional								Total
										Class A								Class B								Paid-in				Accumulated				Shareholders’
		Shares				Amount				Shares				Amount				Shares				Amount				Capital				Deficit				Deficit
Balance as of December 31, 2024			-			$	-				492,000			$	49				2,012,500			$	201			$	-			$	(6,088,320	)		$	(6,088,070	)
Extension funds attributable to ordinary shares subject to redemption			-				-				-				-				-				-				-				(167,471	)			(167,471	)
Accretion of carrying value to redemption value			-				-				-				-				-				-				-				(342,182	)			(342,182	)
Net Income			-				-				-				-				-				-				-				64,931				64,931
Balance as of March 31, 2025			-				-				492,000				49				2,012,500				201			$	-				(6,533,042	)			(6,532,792	)
Extension funds attributable to ordinary shares subject to redemption			-				-				-				-				-				-				-				(167,471	)			(167,471	)
Accretion of carrying value to redemption value			-				-				-				-				-				-				-				(142,759	)			(142,759	)
Issuance of Class A Ordinary Shares upon conversion of working capital loan - related party , and extension loan - related party			-				-				150,000				15				-				-				1,499,985				-				1,500,000
Net Income			-				-				-				-				-				-				-				10,494				10,494
Balance as of June 30, 2025			-			$	-				642,000			$	64				2,012,500			$	201			$	1,499,985			$	(6,832,778	)		$	(5,332,528	)

		For the Six Months Ended June 30, 2024
		Preference shares								Ordinary Shares																Additional								Total
										Class A								Class B								Paid-in				Accumulated				Shareholders’
		Shares				Amount				Shares				Amount				Shares				Amount				Capital				Deficit				Deficit
Balance as of December 31, 2023			-			$	-				492,000			$	49				2,012,500			$	201			$	-			$	(4,474,695	)		$	(4,474,445	)
Extension funds attributable to ordinary shares subject to redemption			-				-				-				-				-				-				-				(255,000	)			(255,000	)
Accretion of carrying value to redemption value			-				-				-				-				-				-				-				(568,384	)			(568,384	)
Net Income			-				-				-				-				-				-				-				438,864				438,864
Balance as of March 31, 2024			-				-				492,000				49				2,012,500				201				-				(4,859,215	)			(4,858,965	)
Extension funds attributable to ordinary shares subject to redemption			-				-				-				-				-				-				-				(180,000	)			(180,000	)
Accretion of carrying value to redemption value			-				-				-				-				-				-				-				(570,206	)			(570,206	)
Net Income			-				-				-				-				-				-				-				438,510				438,510
Balance as of June 30, 2024			-			$	-				492,000			$	49				2,012,500			$	201			$	-			$	(5,170,911	)		$	(5,170,661	)

The accompanying notes are an integral part of these unaudited consolidated financial statements.

3

AIMFINITY INVESTMENT CORP. I

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

		For the Six Months Ended				For the Six Months Ended
		June 30, 2025				June 30, 2024
Cash Flows from Operating Activities:
Net income		$	75,425			$	877,374
Adjustments to reconcile net income to net cash used in operating activities:
Interest earned on cash and investments held in Trust Account			(484,941	)			(1,138,590	)
Changes in operating assets and liabilities:
Prepaid expenses			-				(27,430	)
Accrued expense			191,569				(101,304	)
Net cash used in operating activities			(217,947	)			(389,950	)
Cash Flows from Investing Activities:
Investment of Cash in Trust Account			(334,942	)			(435,000	)
Withdraw of cash and investments held in trust account			23,778,577				9,684,945
Net cash provided by (used in) investing activities			23,443,635				9,249,945
Cash Flows from Financing Activities:
Ordinary shares redemption			(23,778,577	)			(9,684,945	)
Proceeds from extension loan			334,942				435,000
Proceeds from working capital loan			217,947				389,856
Net cash (used in) provided by financing activities			(23,225,688	)			(8,860,089	)
Net Change in Cash			-				(94	)
Cash at beginning of the period			4,895				4,989
Cash at end of the period		$	4,895			$	4,895
Supplemental Disclosure of Non-cash Financing Activities
Extension funds attributable to ordinary shares subject to redemption		$	334,942			$	435,000
Accretion of carrying value to redemption value		$	484,941			$	1,138,590
Issuance of Class A Ordinary Shares upon conversion of working capital loan - related party, and extension loan - related party		$	1,500,000			$	-

The accompanying notes are an integral part of these unaudited consolidated financial statements.

4

Aimfinity Investment Corp. I
Notes To Unaudited Consolidated Financial Statements

Note 1 — Organization, Business Operation

Aimfinity Investment Corp. I (the “Company”) is an organized blank check company incorporated as a Cayman Islands exempted company on July 26, 2021. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar Business Combination with one or more businesses (the “Business Combination”). The Company has selected December 31 as its fiscal year end.

The Company is an early stage emerging growth company and, as such, the Company is subject to all of the risks associated with early stage emerging growth companies.

As of June 30, 2025, the Company had not commenced any operations. The Company’s only activities from July 26, 2021 (inception) to June 30, 2025 were organizational activities, those necessary to prepare for the IPO, described below, and, after the IPO, identifying a target company for an initial business combination. The Company will not generate any operating revenues until after the completion of an initial business combination, at the earliest. The Company will generate non-operating income in the form of interest income from the proceeds derived from the IPO (as defined below).

The registration statement for the Company’s Initial Public Offering (“IPO”) became effective on April 25, 2022. On April 28, 2022 the Company consummated the IPO of 8,050,000 units (including 1,050,000 units issued upon the full exercise of the over-allotment option, the “Public Units”). Each unit consists of one share of the Company’s Class A ordinary share and one Class 1 public warrant and one-half of one Class 2 public warrant. Each whole warrant (whether Class 1 or Class 2) entitles the holder thereof to purchase one share of the Company’s Class A ordinary share at a price of $11.50 per share, and only whole warrants are exercisable. The Units were sold at an offering price of $10.00 per Unit, generating gross proceeds of $80,500,000 on April 28, 2022.

Substantially concurrently with the closing of the IPO, the Company completed the private sale of 492,000 units (the “Private Placement Units”) at a purchase price of $10.00 per Private Placement Unit, generating gross proceeds to the Company of $4,920,000. The Private Placement Unit are identical to the Public Units in the IPO, except that the holders have agreed not to transfer, assign or sell any of the Private Placement Units (except to certain permitted transferees) until 30 days after the completion of the Company’s initial business combination.

Transaction costs amounted to $5,117,607, consisting of $4,427,500 of underwriting fees and $690,107 of other offering costs. As of June 30, 2025 and December 31, 2024, cash of $4,895, were held outside of the Trust Account (as defined below) and is available for working capital purposes.

Following the closing of the IPO and the issuance and the sale of Private Placement Units on April 28, 2022, $82,110,000 ($10.20 per Public Unit) from the net proceeds of the sale of the Public Units in the IPO and the sale of Private Placement Units was placed in a trust account (the “Trust Account”) maintained by U.S. Bank, National Association as a trustee. The funds in the trust account will be invested only in U.S. government treasury obligations with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a 7 under the Investment Company Act which invest only in direct U.S. government treasury obligations. Except with respect to interest earned on the funds held in the trust account that may be released to the Company to pay the franchise and income taxes, if any, the effective memorandum and articles of association at the time and subject to the requirements of law and regulation, will provide that the proceeds from the IPO and the sale of the Private Placement Units held in the trust account will not be released from the Trust Account (1) to the Company, until the completion of the initial business combination, or (2) to the Company’s public shareholders, until the earliest of (a) the completion of the initial business combination, and then only in connection with those Class A ordinary shares that such shareholders properly elected to redeem, subject to the limitations described herein, (b) the redemption of any Class A ordinary shares properly tendered in connection with a shareholder vote to amend the Company’s effective amended and restated memorandum and articles of association at the time (A) to modify the substance or timing of the Company’s obligation to provide holders of the Company’s Class A ordinary shares the right to have their shares redeemed in connection with the initial business combination or to redeem 100% of the Company’s public shares if the Company does not complete the initial business combination by the Combination Deadline (as defined below) or (B) with respect to any other provision relating to the rights of holders of the Company’s Class A ordinary shares, and (c) the redemption of the Company’s public shares if the Company has not consummated an initial business combination by the Combination Deadline, subject to applicable law.

5

Aimfinity Investment Corp. I
Notes To Unaudited Consolidated Financial Statements

The Company’s initial business combination must occur with one or more target businesses that together have an aggregate fair market value of at least 80% of the assets held in the trust account (excluding deferred underwriting commissions and interest income earned on the trust account that is released for working capital purposes or to pay taxes) at the time of the agreement to enter into the initial business combination. However, the Company will only complete an initial business combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires an interest in the target sufficient for the post-transaction company not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the “Investment Company Act”). There is no assurance that the Company will be able to complete an initial business combination successfully.

The ordinary shares subject to redemption will be recorded at a redemption value and classified as temporary equity upon the completion of the Initial Public Offering, in accordance with Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” In such case, the Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and, if the Company seeks shareholder approval, a majority of the issued and outstanding shares voted are voted in favor of the Business Combination.

Following the closing of the IPO, under the Company’s then-effective amended and restated memorandum and articles of association, the Company would have until July 28, 2023 (or January 28, 2024 if the Company extends the period of time to consummate an initial business combination) to consummate an initial business combination. On July 27, 2023, the Company held an extraordinary general meeting of shareholders (the “First EGM”). At the First EGM, the shareholders of the Company, by special resolution, approved the proposal to amend the Company’s then-effective amended and restated memorandum and articles of association (the “First Charter Amendment”) to (i) allow the Company until July 28, 2023 to consummate an initial business combination, and to (ii) elect to extend the period to consummate an initial business combination up to nine times, each by an additional one-month period, for a total of up to nine months to April 28, 2024, by depositing to the Company’s Trust Account the amount lesser of (i) $85,000 for each one-month extension or (ii) $0.04 for each Public Share for each one-month extension (the “First Charter Amendment Proposal”). Under Cayman Islands law, the First Charter Amendment took effect upon approval of the First Charter Amendment Proposal by the shareholders at the First EGM. On July 27, 2023, the Company also filed the First Charter Amendment with the Registrar of Companies of the Cayman Islands. Pursuant to the First Charter Amendment, the Company may, at the request of Aimfinity Investment LLC (the “Sponsor”), and by approval of the Company’s board of directors, elect to extend the period to consummate an initial business combination up to nine times, each by an additional one-month period (each, a “First Charter Amendment Monthly Extension”), for a total of up to nine months to April 28, 2024, by depositing to the Trust Account $85,000 for each First Charter Amendment Monthly Extension.

On April 23, 2024, the Company held a second extraordinary general meeting of shareholders (the “Second EGM”). At the Second EGM, the shareholders of the Company, by special resolution, approved the proposal to amend the Company’s then-effective amended and restated memorandum and articles of association (the “Second Charter Amendment”) to (i) allow the Company until April 28, 2024 to consummate an initial business combination, and to (ii) elect to extend the period to consummate an initial business combination up to nine times, each by an additional one-month period (each a “Second Charter Amendment Monthly Extension”), for a total of up to nine months to January 28, 2025 (the “Combination Deadline”), by depositing to the Company’s Trust Account the amount lesser of (i) $60,000 for each one-month extension or (ii) $0.035 for each Public Share for each one-month extension (the “Second Charter Amendment Monthly Extension”). On April 27, 2024, the Company filed the Second Charter Amendment with the Registrar of Companies of the Cayman Islands.

On May 23, 2024, in connection with the votes to approve the Second Charter Amendment, the holders of 860,884 of Public Shares of the Company exercised their right to redeem their shares for cash at redemption price of approximately $11.25 per share, for an aggregate redemption amount of approximately $9,684,945.

On January 9, 2025, the Company held an extraordinary general meeting (the “Shareholder Meeting”) in lieu of an annual general meeting, which was previously adjourned on December 30, 2024.

6

Aimfinity Investment Corp. I
Notes To Unaudited Consolidated Financial Statements

At the Shareholder Meeting, the shareholders of the Company, by special resolution, approved the proposal to amend Company’s third amended and restated memorandum and articles of associations (the “Charter”), which previously provided that the Company has until April 28, 2024 to complete a Business Combination, and may elect to extend the period to consummate a Business Combination up to nine times, each by an additional one-month extension (each, a “Monthly Extension”), for a total of up to nine months to January 28, 2025, by deleting in their entirety and substituting in their place of the fourth amended and restated memorandum and articles of association of the Company (the “Amended Charter”), which provides that the Company has until January 28, 2025 to complete a Business Combination, and may elect to extend the period to consummate a Business Combination up to nine times, each by an additional Monthly Extension, for a total of up to nine months to October 28, 2025, by depositing to the Company’s trust account (the “Trust Account”) an amount equal to $0.05 for each remaining public share at the time of such deposit.

In connection with the votes to approve the Charter Amendment Proposal, 1,996,522 Class A Ordinary Shares included in the new units of the Company were tendered for redemption. Upon the completion of the redemption of the Class A Ordinary Shares, the Class 2 warrants included in the new units that are attached to the redeemed Class A Ordinary Shares will be automatically forfeited and cancelled without any additional action by the holders.

As of the date of the issuance of these unaudited consolidated financial statements, the total of $1,807,413 was deposited into the Trust Account for the Public Shareholders, resulting in extensions of the period of time the Company has to consummate the initial business combination by October 28, 2025.

If the Company does not consummate an initial business combination by the Combination Deadline, the Company will: (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but no more than ten business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay the franchise and income taxes that were paid by the Company or are payable by the Company, if any (less up to $100,000 of interest to pay dissolution expenses) divided by the number of the then-outstanding Public Shares, which redemption will completely extinguish Public Shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any); and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining shareholders and the Company’s board of directors, liquidate and dissolve, subject in each case to the Company’s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law.

The Founder Shares (as defined in Note 6) are designated as Class B ordinary shares, par value $0.0001 per share (the “Class B ordinary shares”, together with Class A ordinary shares, the “ordinary shares”) of the Company are identical to the Class A ordinary shares included in the units being sold in the IPO, and holders of Founder Shares have the same shareholder rights as Public Shareholders, except that: (a) the founder shares will automatically convert into the Company’s Class A ordinary shares at the time of the initial business combination, (b) the Founder Shares are subject to certain transfer restrictions, as described in more detail below; (c) prior to the initial business combination, only holders of the Founder Shares have the right to vote on the appointment of directors and holders of a majority of the Company’s Founder Shares may remove a member of the board of directors for any reason; (d) in a vote to continue the Company in a jurisdiction outside the Cayman Islands (which requires the approval of at least two thirds of the votes of all ordinary shares voted at a general meeting), holders of the Company’s Founder Shares have ten votes for every Founder Share and, as a result, the Company’s initial shareholders will be able to approve any such proposal without the vote of any other shareholder; (e) the Company’s Sponsor and each member of the management team have entered into an agreement with the Company, pursuant to which they have agreed to (i) waive their redemption rights with respect to their Founder Shares, (ii) to waive their redemption rights with respect to their Founder Shares and Public Shares in connection with a shareholder vote to approve an amendment to the Company’s Charter (A) that would modify the substance or timing of the obligation to provide the Public Shareholders the right to have their Public Shares redeemed in connection with the initial business combination or to redeem 100% of the Company’s Public Shares if the Company does not complete the initial business combination by the Combination Deadline, or (B) with respect to any other provision relating to the rights of holders of the Company’s Class A ordinary shares; and (iii) waive their rights to liquidating distributions from the Trust Account with respect to any Founder Shares they hold if the Company fail to consummate an initial business combination by the Combination Deadline, although they will be entitled to liquidating distributions from the Trust Account with respect to any Public Shares they hold if the Company fails to complete the initial business combination within the prescribed time frame; and (f) the Founder Shares are entitled to registration rights. If the Company seek shareholder approval of the Company’s initial business combination, the Company will complete the initial business combination only if the Company obtains the approval of an ordinary resolution under Cayman Islands law, which requires the affirmative vote of a majority of the shareholders who attend and vote at a general meeting of the Company. In such case, the Company’s Sponsor and each member of the management team have agreed to vote their Founder Shares and Public Shares in favor of the initial business combination.

7

Aimfinity Investment Corp. I
Notes To Unaudited Consolidated Financial Statements

The Founder Shares will automatically convert into Class A ordinary shares at the time of the initial business combination at a ratio such that the number of Class A ordinary shares issuable upon conversion of all Founder Shares will equal, in the aggregate, on an as-converted basis, approximately 20% of the sum of (i) the total number of ordinary shares issued and outstanding upon completion of the IPO, plus (ii) the total number of Class A ordinary shares issued or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the consummation of the initial business combination, excluding any Class A ordinary shares or equity-linked securities exercisable for or convertible into Class A ordinary shares issued, deemed issued, or to be issued, to any seller in the initial business combination and any private placement units issued to the Company’s Sponsor, its affiliates or any member of the management team upon conversion of working capital loans. In no event will the Class B ordinary shares convert into Class A ordinary shares at a rate of less than one-to-one.

The Sponsor, Aimfinity Investment LLC, has agreed that it will be liable to the Company if and to the extent any claims by a third party (other than the Company’s registered public accounting firm) for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amounts in the Trust Account to below the lesser of (i) $10.20 per Public Share and (ii) the actual amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account if less than $10.20 per Public Share due to reductions in the value of the trust assets, in each case net of the interest that may be withdrawn to pay the Company’s tax obligations, provided that such liability will not apply to any claims by a third-party or prospective target business that executed a waiver of any and all rights to seek access to the Trust Account nor will it apply to any claims under the indemnity of the underwriters of the IPO against certain liabilities, including liabilities under the Securities Act. Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims.

The Merger Agreement

On October 13, 2023, the Company entered into that certain Agreement and Plan of Merger (as may be amended, supplemented or otherwise modified from time to time, the “Merger Agreement”) with Docter Inc., a Delaware corporation (the “Docter”), Aimfinity Investment Merger Sub I, a Cayman Islands exempted company and wholly-owned subsidiary of the Company (“Purchaser”), and Aimfinity Investment Merger Sub II, Inc., a Delaware corporation and wholly-owned subsidiary of Purchaser (“Merger Sub”), pursuant to which (a) Company will be merged with and into Purchaser (the “Reincorporation Merger”), with Purchaser surviving the Reincorporation Merger, and (b) Merger Sub will be merged with and into the Docter (the “Acquisition Merger”), with Docter surviving the Acquisition Merger as a direct wholly owned subsidiary of Purchaser (collectively, the “Business Combination”). Following consummation of the Business Combination (the “Closing”), Purchaser will be a publicly traded company (Purchaser is sometimes referred to herein as “PubCo”, upon and following the consummation of the Reincorporation Merger).

On April 5, 2024, the Company, Purchaser, Merger Sub and Target entered into an amendment to the Business Combination Agreement (the “Amendment No. 1”) to modify the composition of PubCo’s board of directors upon and immediately following the completion of the Business Combination.

On January 29, 2025, Aimfinity, Purchaser, Merger Sub and Docter entered into an amendment to the Merger Agreement (the “Amendment No. 2”) to modify the earnout arrangement as follows:

● 1,000,000 Earnout Shares will be issued to each Docter Stockholder on a pro rata basis if and only if PubCo completes sales of at least 30,000 Devices (as defined in the Merger Agreement) during fiscal year 2025 as reflected in its audited consolidated annual financial statements for the fiscal year ending December 31, 2025 prepared in accordance with the U.S. GAAP as filed with the SEC;

8

Aimfinity Investment Corp. I
Notes To Unaudited Consolidated Financial Statements

● 1,500,000 Earnout Shares will be issued to each Docter Stockholder on a pro rata basis if and only if PubCo completes sales of at least 40,000 Devices during fiscal year 2026 as reflected in its audited consolidated annual financial statements for the fiscal year ending December 31, 2026 prepared in accordance with the U.S. GAAP as filed with the SEC.

Going Concern Consideration

As of June 30, 2025, the Company had cash of $4,895 and a working deficit of $2,515,028. The Company has incurred and expects to continue to incur significant professional costs to remain as a publicly traded company and to incur significant transaction costs in pursuit of the consummation of an initial business combination.

The Company’s cash and working capital as of June 30, 2025, are not sufficient to complete its planned activities to consummate an initial business combination for the upcoming year. In connection with the Company’s assessment of going concern considerations in accordance with Financial Accounting Standard Board’s (“FASB”) Accounting Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” management has determined that these conditions raise substantial doubt about the Company’s ability to continue as a going concern. In addition, if the Company is unable to complete an initial business combination by the Combination Deadline, the Company’s board of directors would proceed to commence a voluntary liquidation and thereby a formal dissolution of the Company. There is no assurance that the Company’s plans to consummate an initial business combination will be successful by the Combination Deadline. As a result, management has determined that such additional conditions also raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the unaudited consolidated financial statements are issued. The unaudited consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Risks and Uncertainties

As a result of the military action commenced in February 2022 by the Russian Federation and Belarus in the country of Ukraine and related economic sanctions, the Company’s ability to consummate an initial business combination, or the operations of a target business with which the Company ultimately consummates an initial business combination, may be materially and adversely affected. In addition, the Company’s ability to consummate a transaction may be dependent on the ability to raise equity and debt financing which may be impacted by these events, including as a result of increased market volatility, or decreased market liquidity in third-party financing being unavailable on terms acceptable to the Company or at all. The impact of this action and related sanctions on the world economy and the specific impact on the Company’s financial position, results of operations and/or ability to consummate an initial business combination are not yet determinable. The unaudited consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Note 2 — Significant Accounting Policies

Basis of Presentation

The accompanying unaudited consolidated financial statements are presented in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Interim results are not necessarily indicative of results to be expected for any other interim period or for the full year. The information included in this Form 10-Q should be read in conjunction with information included in the Company’s annual report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission on April 15, 2025.

9

Aimfinity Investment Corp. I
Notes To Unaudited Consolidated Financial Statements

Principles of consolidation

The unaudited consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries, Purchase and Merger Sub, over which the Company exercises control. All transactions and balances among the Company and its subsidiaries have been eliminated upon consolidation.

Emerging Growth Company Status

The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended, (the “Securities Act”), as modified by the Jumpstart The Company’s Business Startups Act of 2012, (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statement, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.

Further, Section 102(b) (1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statement with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

Use of Estimates

The preparation of financial statement in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period.

Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statement, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.

Cash and Cash Equivalents

The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had $4,895 in cash as of June 30, 2025 and December 31, 2024. The Company had no cash equivalents as of June 30, 2025 and December 31, 2024.

Cash and Investments held in Trust Account

As of June 30, 2025 and December 31, 2024, the assets held in the Trust Account were held in money market funds, which invest in U.S. Treasury securities.

Earnings on investments held in the Trust Account are included in interest earned on cash and investments held in the Trust Account in the accompanying statement of operations. The estimated fair value of investments held in the Trust Account is determined using available market information.

Warrants

The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) ASC 480 “Distinguishing Liabilities from Equity” (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, whether they meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own Ordinary Shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.

10

Aimfinity Investment Corp. I
Notes To Unaudited Consolidated Financial Statements

For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of equity at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as liabilities at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations. (See Note 8).

Ordinary Shares Subject to Possible Redemption

The Company accounts for its ordinary shares subject to possible redemption in accordance with the guidance in ASC Topic 480 “Distinguishing Liabilities from Equity.” ordinary shares subject to mandatory redemption (if any) are classified as a liability instrument and are measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, ordinary shares are classified as stockholders’ equity. The Company’s Public Shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, as of June 30, 2025 and December 31, 2024, ordinary shares subject to possible redemption are presented at redemption value of $12.52 and $11.87 per share, respectively, as temporary equity, outside of the stockholders’ equity section of the Company’s balance sheet. The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable Ordinary Shares to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable Class A ordinary shares are affected by charges against additional paid in capital or accumulated deficit if additional paid in capital equals to zero.

Net (Loss) Income Per Ordinary Share

The Company complies with accounting and disclosure requirements of FASB ASC 260, Earnings Per Share. In order to determine the net (loss) income attributable to both the redeemable shares and non-redeemable shares, the Company first considered the undistributed income (loss) allocable to both the redeemable shares and non-redeemable shares and the undistributed income (loss) is calculated using the total net income (loss) less interest and dividend income and unrealized gain or loss on investments in the Trust Account less any dividends paid. The Company then allocated the undistributed income (loss) ratably based on the weighted average number of shares outstanding between the redeemable and non-redeemable shares. Any remeasurement of the accretion to redemption value of the ordinary shares subject to possible redemption was considered to be dividends paid to the Public Shareholders. As of June 30, 2025 and December 31, 2024, the Company did not have any dilutive securities and other contracts that could, potentially, be exercised or converted into ordinary shares and then shared in the earnings of the Company. As a result, diluted income (loss) per share is the same as basic income (loss) per share for the period presented.

11

Aimfinity Investment Corp. I
Notes To Unaudited Consolidated Financial Statements

The net income (loss) per share presented in the statement of operations is based on the following:

		For the Three Months				For the Three Months				For the Six Months				For the Six Months
		Ended				Ended				Ended				Ended
		June 30, 2025				June 30, 2024				June 30, 2025				June 30, 2024
Net income		$	10,494			$	438,510			$	75,425			$	877,374
Accretion of carrying value to redemption value			(310,230	)			(750,206	)			(819,883	)			(1,573,590	)
Net loss including accretion of carrying value of Redemption value		$	(299,736	)		$	(311,696	)		$	(744,458	)		$	(696,216	)

		For the Three Months Ended								For the Three Months Ended
		June 30, 2025								June 30, 2024
		Redeemable				Non-Redeemable				Redeemable				Non-Redeemable
		Common				Common				Common				Common
		Stock				Stock				Stock				Stock
Basic and diluted net income (loss) per share:
Numerators:
Allocation of net loss including carrying value to redemption value		$	(89,055	)		$	(210,681	)		$	(184,117	)		$	(127,579	)
Accretion of carrying value to redemption value			310,230				-				750,206				-
Allocation of net income/(loss)		$	221,175			$	(210,681	)		$	566,089			$	(127,579	)
Denominators:
Weighted-average shares outstanding			1,116,476				2,641,313				3,614,392				2,504,500
Basic and diluted net income/ (loss) per share		$	0.20			$	(0.08	)		$	0.16			$	(0.05	)

		For the Six Months Ended								For the Six Months Ended
		June 30, 2025								June 30, 2024
		Redeemable				Non-Redeemable				Redeemable				Non-Redeemable
		Common				Common				Common				Common
		Stock				Stock				Stock				Stock
Basic and diluted net income (loss) per share:
Numerators:
Allocation of net loss including carrying value to redemption value		$	(279,831	)		$	(464,627	)		$	(419,383	)		$	(276,833	)
Accretion of carrying value to redemption value			819,883				-				1,573,590				-
Allocation of net income/(loss)		$	540,052			$	(464,627	)		$	1,154,207			$	(276,833	)
Denominators:
Weighted-average shares outstanding			1,590,788				2,641,313				3,794,137				2,504,500
Basic and diluted net income/ (loss) per share		$	0.34			$	(0.18	)		$	0.30			$	(0.11	)

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account. As of June 30, 2025 and December 31, 2024, none was over the Federal Deposit Insurance Corporation (FDIC) limit.

12

Aimfinity Investment Corp. I
Notes To Unaudited Consolidated Financial Statements

Fair Value of Financial Instruments

ASC Topic 820 “Fair Value Measurements and Disclosures” defines fair value, the methods used to measure fair value and the expanded disclosures about fair value measurements. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between the buyer and the seller at the measurement date. In determining fair value, the valuation techniques consistent with the market approach, income approach and cost approach shall be used to measure fair value. ASC Topic 820 establishes a fair value hierarchy for inputs, which represent the assumptions used by the buyer and seller in pricing the asset or liability. These inputs are further defined as observable and unobservable inputs. Observable inputs are those that buyer and seller would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs reflect the Company’s assumptions about the inputs that the buyer and seller would use in pricing the asset or liability developed based on the best information available in the circumstances.

The fair value hierarchy is categorized into three levels based on the inputs as follows:

● Level 1 - Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Valuation adjustments and block discounts are not being applied. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these securities does not entail a significant degree of judgment.

● Level 2 - Valuations based on (i) quoted prices in active markets for similar assets and liabilities, (ii) quoted prices in markets that are not active for identical or similar assets, (iii) inputs other than quoted prices for the assets or liabilities, or (iv) inputs that are derived principally from or corroborated by market through correlation or other means.

● Level 3 - Valuations based on inputs that are unobservable and significant to the overall fair value measurement.

The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC Topic 820, “Fair Value Measurements and Disclosures,” approximates the carrying amounts represented in the accompanying balance sheet, primarily due to their short-term nature.

Income Taxes

The Company accounts for income taxes under ASC 740 Income Taxes (“ASC 740”). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized.

ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statement and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition.

The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of June 30, 2025 and December 31, 2024. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position.

13

Aimfinity Investment Corp. I
Notes To Unaudited Consolidated Financial Statements

The Company determined that the Cayman Islands is the Company’s only major tax jurisdiction and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. In accordance with Cayman income tax regulations, income taxes are not levied on the Company.

The Company may be subject to potential examination by federal and state taxing authorities in the areas of income taxes. These potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.

The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of June 30, 2025 and December 31, 2024. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position.

Recent Accounting Pronouncements

On November 4, 2024, the FASB issued ASU No. 2024-03, Expense Disaggregation Disclosures (“ASU 2024-03”). ASU 2024-03 amends ASC 220, Comprehensive Income to expand income statement expense disclosures and require disclosure in the notes to the financial statements of specified information about certain costs and expenses. ASU 2024-03 is required to be adopted for fiscal years commencing after December 15, 2026, with early adoption permitted. The Company is currently evaluating the impact of adopting the standard on the Company’s unaudited consolidated financial statements.

Except as mentioned above, the Company does not believe other recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the Company’s unaudited consolidated balance sheets, statements of operations and statements of cash flow.

Note 3 — Cash and Investments Held in Trust Account

As of June 30, 2025 and December 31, 2024, assets held in the Trust Account were comprised of $13,981,534 and $36,940,228, respectively, in money market funds which invest in U.S. Treasury Securities.

The following table presents information about the Company’s assets that are measured at fair value on a recurring basis as of June 30, 2025 and December 31, 2024 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:

		Level				June 30, 2025				December 31, 2024
Assets:
Trust Account – U.S. Treasury Securities Money Market Fund			1			$	13,981,534			$	36,940,228

Note 4 — Initial Public Offering

Pursuant to the IPO on April 28, 2022, the Company sold 8,050,000 Public Units at $10.00 per Public Unit, generating gross proceeds of $80,500,000. Each Public Unit consists of one Public Share and one Class 1 warrant and one-half of one Class 2 warrant. The Company will not issue fractional shares. As a result, the warrants must be exercised in multiples of one whole warrant. Each whole warrant entitles the holder thereof to purchase one share of the Company’s Public Share at a price of $11.50 per share, and only whole warrants are exercisable. The warrants will become exercisable on the later of 30 days after the completion of the initial business combination or 12 months from the closing of the IPO, and will (except for Class 2 Warrants embedded in the Public Shares that are redeemed prior to the consummation of the initial business combination, which Class 2 warrant will be forfeited and cancelled upon redemption of such shares) expire five years after the completion of the initial business combination or earlier upon redemption or liquidation. As a result, if the Public Shareholders redeem their Public Shares prior to the consummation of the initial business combination, the embedded Class 2 warrant will be forfeited and cancelled.

The Class 1 and Class 2 warrants have similar terms, except that following June 14, 2022, the 52nd day following the effective date of the IPO, the holders of the Public Units have the option to separate the Public Units into one Class 1 warrant and one new units of the Company (the “New Units”, with each consisted of one Class A ordinary share and one-half of one Class 2 warrant), and to have the Class 1 warrants and new Units separately traded on the Nasdaq Global Market. The holders of the New Units resulting from such separation will not have the option to separate such New Units into its components, the Class A ordinary shares and the Class 2 warrants, for separate trading until consummation of the initial business combination.

14

Aimfinity Investment Corp. I
Notes To Unaudited Consolidated Financial Statements

All of the 8,050,000 Public Shares sold as part of the Public Units in the IPO contain a redemption feature which allows for the redemption of such Public Shares if there is a stockholder vote or tender offer in connection with an initial business combination and in connection with certain amendments to the Company’s effective amended and restated certificate of incorporation at the time, or in connection with the Company’s liquidation. In accordance with the Securities and Exchange Commission (the “SEC”) and its staff’s guidance on redeemable equity instruments, which has been codified in ASC 480-10-S99, redemption provisions not solely within the control of the Company require ordinary shares subject to redemption to be classified outside of permanent equity.

The Company’s redeemable Class A ordinary shares is subject to SEC and its staff’s guidance on redeemable equity instruments, which has been codified in ASC 480-10-S99. If it is probable that the equity instrument will become redeemable, the Company has the option to either accrete changes in the redemption value over the period from the date of issuance (or from the date that it becomes probable that the instrument will become redeemable, if later) to the earliest redemption date of the instrument or to recognize changes in the redemption value immediately as they occur and adjust the carrying amount of the instrument to equal the redemption value at the end of each reporting period. The Company has elected to recognize the changes immediately. The accretion or remeasurement is treated as a deemed dividend (i.e., a reduction to retained earnings, or in absence of retained earnings, additional paid-in capital).

As of June 30, 2025 and December 31, 2024, the amounts of ordinary shares reflected on the balance sheet are reconciled in the following table. 

Ordinary shares subject to possible redemption, December 31, 2023		$	43,794,663
Less:
Redemptions			(9,684,945	)
Plus:
Extension funds attributable to ordinary shares subject to redemption			795,000
Accretion of carrying value to redemption value			2,035,510
Ordinary shares subject to possible redemption, December 31, 2024		$	36,940,228
Less:
Redemptions			(23,778,577	)
Plus:
Extension funds attributable to ordinary shares subject to redemption			334,942
Accretion of carrying value to redemption value			484,941
Ordinary shares subject to possible redemption, June 30, 2025		$	13,981,534

On January 9, 2025, the Company held an extraordinary general meeting (the “Shareholder Meeting”) in lieu of an annual general meeting, which was previously adjourned on December 30, 2024.

At the Shareholder Meeting, the shareholders of the Company, by special resolution, approved the proposal to amend Company’s third amended and restated memorandum and articles of associations (the “Charter”), which previously provided that the Company has until April 28, 2024 to complete a Business Combination, and may elect to extend the period to consummate a Business Combination up to nine times, each by an additional one-month extension (each, a “Monthly Extension”), for a total of up to nine months to January 28, 2025, by deleting in their entirety and substituting in their place of the fourth amended and restated memorandum and articles of association of the Company (the “Amended Charter”), which provides that the Company has until January 28, 2025 to complete a Business Combination, and may elect to extend the period to consummate a Business Combination up to nine times, each by an additional Monthly Extension, for a total of up to nine months to October 28, 2025, by depositing to the Company’s trust account (the “Trust Account”) an amount equal to $0.05 for each remaining public share at the time of such deposit.

In connection with the votes to approve the Charter Amendment Proposal, 1,996,522 Class A Ordinary Shares included in the new units of the Company were tendered for redemption. Upon the completion of the redemption of the Class A Ordinary Shares, the Class 2 warrants included in the new units that are attached to the redeemed Class A Ordinary Shares will be automatically forfeited and cancelled without any additional action by the holders. As of June 30, 2025, the Company completed the redemption of 1,996,522 Class A ordinary shares for a total redemption amount of $23,778,577.

15

Aimfinity Investment Corp. I
Notes To Unaudited Consolidated Financial Statements

Note 5 — Private Placement

Simultaneously with the closing of the IPO, the Company completed the private placement of 492,000 Private Placement Units to the Company’s Sponsor, Aimfinity Investment LLC, at a purchase price of $10.00 per Private Placement Unit, generating gross proceeds to the Company of $4,920,000. Each Private Placement Unit consists of one Class A ordinary share, one Class 1 warrant and one-half of one Class 2 Warrant.

The Sponsor will be permitted to transfer the Private Placement Units held by them to certain permitted transferees, including the Company’s officers and directors and other persons or entities affiliated with or related to it or them, but the transferees receiving such securities will be subject to the same agreements with respect to such securities as the founders. Otherwise, these Private Placement Units will not, subject to certain limited exceptions, be transferable or saleable until 30 days after the completion of the Company’s business combination. The warrants included in the Private Placement Units will not be transferable, assignable or saleable until 30 days after the completion of the Company’s initial business combination (except as described herein). Otherwise, the warrants have terms and provisions that are identical to those of the warrants being sold as part of the Units in the IPO, including as to exercise price, exercisability and exercise period.

Note 6 — Related Party Transactions

Founder Shares

On December 4, 2021, the Sponsor acquired 2,875,000 founder shares for an aggregate purchase price of $25,000, or approximately $0.009 per share. On March 18, 2022, the Sponsor surrendered to the Company for cancellation 862,500 founder shares for no consideration, resulting in the Company’s initial shareholders holding an aggregate of 2,012,500 Class B ordinary shares, or approximately $0.012 per share. As of June 30, 2025 and December 31, 2024, there were 2,012,500 founder shares issued and outstanding.

On March 29, 2022, the Sponsor transferred 20,000 founder shares to the Chief Financial Officer of the Company and 60,000 founder shares to certain members of the board of directors. If the officer and director nominee do not become an officer or director of the Company at the time of the Company’s initial public offering, is removed from office as director, or voluntarily resigns his position with the Company before a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar Business Combination involving the Company (“the Triggering Event”), all of such shares shall be returned to Sponsor. Further, considering that in case an initial business combination does not occur these awards will be forfeited, it was deemed that the above terms result in the vesting provision whereby the share awards would vest only upon the consummation of an initial business combination or change of control event. As a result, any compensation expense in relation to these grants will be recognized at the Triggering Event. As a result, the Company recorded no compensation expense for the six months ended June 30, 2025 and 2024.

The fair value of the founder shares on the grant date was approximately $1.37 per share. The valuation performed by the Company determined the fair value of the shares on the date of grant by applying a discount based upon a) the probability of a successful IPO, b) the probability of a successful Business Combination, and c) the lack of marketability of the Founder Shares. The aggregate grant date fair value of the awards amounted to approximately $111,774.

As of June 30, 2025, the Company determined that an initial business combination is not considered probable, and therefore, no stock-based compensation expense has been recognized. Total unrecognized compensation expense related to unvested founder shares as of June 30, 2025 amounted to approximately $111,744 and is expected to be recognized upon the Triggering Event.

The founder shares are designated as Class B ordinary shares and will automatically convert into Class A ordinary shares at the time of the initial Business Combination at a ratio such that the number of Class A ordinary shares issuable upon conversion of all founder shares will equal, in the aggregate, on an as-converted basis, approximately 20% of the sum of (i) the total number of ordinary shares issued and outstanding upon completion of the IPO, plus (ii) the total number of Class A ordinary shares issued or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the consummation of the initial Business Combination, excluding any Class A ordinary shares or equity-linked securities exercisable for or convertible into Class A ordinary shares issued, deemed issued, or to be issued, to any seller in the initial Business Combination and any private placement units issued to the Company’s sponsor, its affiliates or any member of the management team upon conversion of working capital loans. In no event will the Class B ordinary shares convert into Class A ordinary shares at a rate of less than one-to-one.

16

Aimfinity Investment Corp. I
Notes To Unaudited Consolidated Financial Statements

With certain limited exceptions, The Company’s sponsor and each member of the management team have agreed not to transfer, assign or sell any of their founder shares until the earliest of (A) one year after the completion of the initial Business Combination and (B) subsequent to the initial Business Combination, (x) if the closing price of the Company’s Class A ordinary shares equals or exceeds $12.00 per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after the initial Business Combination, or (y) the date on which the Company completes a liquidation, merger, share exchange or other similar transaction that results in all of the Company’s public shareholders having the right to exchange their ordinary shares for cash, securities or other property. The Company refers to such transfer restrictions throughout this prospectus as the lock-up. Any permitted transferees would be subject to the same restrictions and other agreements of the Company’s sponsor and directors and executive officers with respect to any founder shares.

Extension Loans — Related Party

As of June 30, 2025 and December 31, 2024, a total of $1,639,942 and $1,305,000 were deposited into the Trust Account for the public shareholders, resulting in extending the consummation of the initial business combination by April 28, 2025.

In April 2025, $55,824 have been deposited into the Trust Account for the Public Shareholders, resulting in additional one extensions of the period of time Aimfinity has to consummate the initial business combination by May 28, 2025.

The Notes bear no interest and are payable in full upon the earlier to occur of (i) the consummation of the Company’s business combination or (ii) the date of expiry of the term of the Company (the “Maturity Date”). The following shall constitute an event of default: (i) a failure to pay the principal within five business days of the Maturity Date; (ii) the commencement of a voluntary or involuntary bankruptcy action, (iii) the breach of the Company’s obligations thereunder; (iv) any cross defaults; (v) an enforcement proceedings against the Company; and (vi) any unlawfulness and invalidity in connection with the performance of the obligations thereunder, in which case the Note may be accelerated.

The payee of the Notes has the right, but not the obligation, to convert the Promissory Note, in whole or in part, respectively, into private units (the “Private Units”) of the Company, that are identical to the Private Units issued by the Company in the private placement consummated simultaneously with the Company’s initial public offering. The number of Private Units to be received by the Sponsor in connection with such conversion shall be an amount determined by dividing (x) the sum of the outstanding principal amount payable to the Sponsor by (y) $10.00.

On April 8, 2025, the Company entered into an Exchange Agreement with Docter Inc., its merger subsidiaries, and Mr. I-Fa Chang, manager of the Company’s sponsor, in connection with its previously announced business combination with Docter. Under the agreement, the Company agreed to convert an aggregate of $1,500,000 of outstanding promissory notes, consisting of $1,472,471 in extension-related loans and $27,529 in working capital loans, into 150,000 private units.

As of June 30, 2025 and December 31, 2024, the Company has an outstanding loan balance of $167,471 and $1,305,000, respectively.

Payable – Related Party

The Company entered an office lease agreement with Regus. The lease term is one year from December 2021 and December 2022 at $3,332 per month. The leased office was not occupied by the Company until May 1, 2022 after the Company completed the IPO. The Sponsor make the payments for rent and is reimbursed the amounts from the Company. In March 2023, the lease agreement was terminated. The Sponsor is providing rent at no cost to the Company. During the year of 2023, the Company borrowed $17,823 from a Sponsor to pay certain operating expenses.

17

Aimfinity Investment Corp. I
Notes To Unaudited Consolidated Financial Statements

As of June 30, 2025 and December 31, 2024, the Company had $0 payable to the Sponsor. This payable is non-interest bearing, unsecured and is due on demand.

Working Capital Loans

On December 8, 2023 and on April 4, 2024, the Company issued two promissory note to I-Fa Chang, as the designee, sole member and manager of the Sponsor, under which I-Fa Chang agreed to loan the Company up to $1,000,000 to be used for a portion of the working capital. This loan is non-interest bearing, unsecured and is due at the earlier of (1) the date on which the Company consummates its initial business combination or (2) the date on which the Company liquidates and dissolves. I-Fa Chang, as the payee, has the right, but not the obligation, to convert the note, in whole or in part, into Private Placement Units of the Company, that are identical to the Private Placement Units issued by the Company in the Private Placement consummated simultaneously with the Company’s IPO, subject to certain exceptions, as described in the IPO Prospectus, by providing the Company with written notice of the intention to convert at least two business days prior to the closing of the initial business combination. The number of Private Placement Units to be received by I-Fa Chang in connection with such conversion shall be an amount determined by dividing (x) the sum of the outstanding principal amount payable to I-Fa Chang by (y) $10.00.

On October 21, 2024, the Company issued a promissory note to I-Fa Chang, as the designee, sole member and manager of the Sponsor, under which I-Fa Chang agreed to loan the Company up to $1,500,000 to be used for a portion of the working capital. This loan is non-interest bearing, unsecured and is due at the earlier of (1) the date on which the Company consummates its initial business combination or (2) the date on which the Company liquidates and dissolves. Mr. Chang, as the payee, has the right, but not the obligation, to convert the note, in whole or in part, into Private Placement Units of the Company, that are identical to the Private Placement Units issued by the Company in the Private Placement consummated simultaneously with the Company’s IPO, subject to certain exceptions, as described in the IPO Prospectus, by providing the Company with written notice of the intention to convert at least two business days prior to the closing of the Initial Business Combination. The number of Private Placement Units to be received by Mr. Chang in connection with such conversion shall be an amount determined by dividing (x) the sum of the outstanding principal amount payable to Mr. Chang by (y) $10.00.

On April 8, 2025, the Company entered into an Exchange Agreement with Docter Inc., its merger subsidiaries, and Mr. I-Fa Chang, manager of the Company’s sponsor, in connection with its previously announced business combination with Docter. Under the agreement, the Company agreed to convert an aggregate of $1,500,000 of outstanding promissory notes, consisting of $1,472,471 in extension-related loans and $27,529 in working capital loans, into 150,000 private units.

As of June 30, 2025 and December 31, 2024, the balance of the working capital loan are $1,393,270 and $1,202,852, respectively.

Note 7 — Commitments & Contingencies

Registration Rights

The holders of the founder shares, private placement shares and private placement warrants, including any of those issued upon conversion of working capital loans (and any Class A ordinary shares issuable upon the exercise of the private placement warrants that may be issued upon conversion of working capital loans) will be entitled to registration rights pursuant to a registration and shareholder rights agreement to be signed prior to or on the effective date of this offering. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company registers such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statement filed after the completion of the initial business combination. However, the registration and shareholder rights agreement provides that the Company will not permit any registration statement filed under the Securities Act to become effective until termination of the applicable lockup period, which occurs (i) in the case of the founder shares, and (ii) in the case of the private placement units and the respective Class A ordinary shares underlying such units, 30 days after the completion of the initial business combination. The Company will bear the expenses incurred in connection with the filing of any such registration statement. In addition, pursuant to the registration and shareholder rights agreement, the Company’s sponsor, upon and following consummation of an initial business combination, will be entitled to nominate three individuals for appointment to the Company’s board of directors, as long as the sponsor holds any securities covered by the registration and shareholder rights agreement.

18

Aimfinity Investment Corp. I
Notes To Unaudited Consolidated Financial Statements

Underwriters Agreement

The underwriters are entitled to underwriting discounts of (i) $0.20 per Public Unit, or $1,610,000 in the aggregate, paid at the closing of the IPO and(ii) a deferred underwriting discount of $0.35 per Public Unit, or approximately $2,817,500 in the aggregate, upon the consummation of the Company’s initial Business Combination. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a business combination, subject to the terms of the underwriting agreement.

On June 13, 2025, the Company, Pubco, Merger Sub, and Docter entered into agreements for the satisfaction and discharge of indebtedness (each a “Discharge Agreement”, together, the “Discharge Agreements”) with D. Boral Capital LLC (f/k/a EF Hutton LLC, division of Benchmark Investments, LLC, “D. Boral”) and US Tiger Securities, Inc. (“US Tiger”), respectively. D. Boral and US Tiger were the underwriters (collectively, the “Underwriters”) of the initial public offering of AIMUF (“IPO”) and the Discharge Agreements have identical terms and conditions. Pursuant to the Discharge Agreements, in lieu of payment of the deferred underwriting commission of $2,817,500 (“Deferred Commission”), each of D. Boral and US Tiger will accept (1) $80,000 in cash at Closing; and (2) 132,875 Purchaser Ordinary Shares at Closing, subject to any adjustments as provided in the Discharge Agreement.

Note 8 — Shareholders’ Deficit

Preference Shares — The Company is authorized to issue 1,000,000 preference shares, $0.0001 par value, with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors. As of June 30, 2025 and December 31, 2024, there were no preference shares issued or outstanding.

Class A Ordinary Shares — The Company is authorized to issue 200,000,000 Class A ordinary shares with a par value of $0.0001 per share. As of June 30, 2025 and December 31, 2024, there were 642,000, and 492,000 Class A ordinary shares issued and outstanding (excluding 1,116,476 shares and 3,112,998 shares subject to possible redemption as of June 30, 2025 and December 31, 2024, respectively).

On April 8, 2025, the Company entered into an Exchange Agreement with Docter Inc., its merger subsidiaries, and Mr. I-Fa Chang, manager of the Company’s sponsor, in connection with its previously announced business combination with Docter. Under the agreement, the Company agreed to convert an aggregate of $1,500,000 of outstanding promissory notes, consisting of $1,472,471 in extension-related loans and $27,529 in working capital loans, into 150,000 private units.

Class B Ordinary Shares — The Company is authorized to issue 20,000,000 Class B ordinary shares with a par value of $0.0001 per share. On December 4, 2021, the Company issued 2,875,000 Class B ordinary shares. On March 18, 2022, the Sponsor surrendered to the Company for cancellation 862,500 Class B ordinary shares for no consideration, resulting in the Company’s initial shareholders holding an aggregate of 2,012,500 so that the initial shareholders will collectively own 20% of the Company’s issued and outstanding ordinary shares after IPO. As of June 30, 2025 and December 31, 2024, there were 2,012,500 Class B ordinary shares issued and outstanding.

Public shareholders of record are entitled to one vote for each share held on all matters to be voted on by shareholders. Except as described below, holders of Class A ordinary shares and holders of Class B ordinary shares will vote together as a single class on all matters submitted to a vote of the Company’s shareholders except as required by law. Unless specified in the Company’s effective amended and restated memorandum and articles of association at the time, or as required by applicable provisions of the Companies Act or applicable stock exchange rules, the affirmative vote of a majority of the Company’s ordinary shares that are voted is required to approve any such matter voted on by the Company’s shareholders. Approval of certain actions will require a special resolution under Cayman Islands law, being the affirmative vote of at least two-thirds of the Company’s ordinary shares that are voted, and pursuant to the amended and restated memorandum and articles of association; such actions include amending the amended and restated memorandum and articles of association and approving a statutory merger or consolidation with another company. The Company’s board of directors is divided into three classes, each of which will generally serve for a term of three years with only one class of directors being appointed in each year. There is no cumulative voting with respect to the appointment of directors, with the result that the holders of more than 50% of the shares voted for the appointment of directors can appoint all of the directors. The shareholders are entitled to receive ratable dividends when, as and if declared by the board of directors out of funds legally available therefor. Prior to the initial Business Combination, (i) only holders of the Company’s founder shares will have the right to vote on the appointment of directors and (ii) in a vote to continue the Company in a jurisdiction outside the Cayman Islands (which requires the approval of at least two thirds of the votes of all ordinary shares voted at a general meeting), holders of the Company’s Class B ordinary shares will have ten votes for every Class B ordinary share and holders of the Company’s Class A ordinary shares will have one vote for every Class A ordinary share. These provisions of the Company’s amended and restated memorandum and articles of association may only be amended by a special resolution passed by not less than 90% of the Company’s ordinary shares who attend and vote at the Company’s general meeting which shall include the affirmative vote of a simple majority of the Company’s Class B ordinary shares. Holders of the Company’s Public Shares will not be entitled to vote on the appointment of directors prior to the initial Business Combination. In addition, prior to the completion of an initial Business Combination, holders of a majority of the Company’s founder shares may remove a member of the board of directors for any reason. In connection with the initial Business Combination, the Company may enter into a shareholders agreement or other arrangements with the shareholders of the target with respect to voting and other corporate governance matters following completion of the initial Business Combination.

19

Aimfinity Investment Corp. I
Notes To Unaudited Consolidated Financial Statements

Warrants — Each whole warrant entitles the registered holder to purchase one Class A ordinary share at a price of $11.50 per share, subject to adjustment as discussed below, at any time commencing on the later of 12 months from the closing of this offering and 30 days after the completion of the initial business combination, except as discussed in the immediately succeeding paragraph. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. The warrants will (except for Class 2 redeemable warrants attached to shares that are redeemed in connection with the initial business combination, which Class 2 redeemable warrants will expire upon redemption of such shares) expire five years after the completion of the initial business combination, at 5:00 p.m., New York City time, or earlier upon redemption or liquidation.

As of June 30, 2025, 8,542,000 Class 1 Warrants and 1,802,499 Class 2 Warrants   are outstanding. (including 492,000 Class 1 Warrants and 246,000 Class 2 Warrants underlying the Private Placement Units). As of December 31, 2024, 8,542,000 Class 1 Warrants and 1,802,499 Class 2 Warrants are outstanding (including 492,000 Class 1 Warrants and 246,000 Class 2 Warrants underlying the Private Placement Units). The Company will account for warrants as equity instruments in accordance with ASC 815, Derivatives and Hedging, based on the specific terms of the warrant agreement.

The Company has agreed that as soon as practicable, but in no event later than 20 business days, after the closing of the initial Business Combination, the Company will use its commercially reasonable efforts to file with the SEC a registration statement for the registration, under the Securities Act, of the Class A ordinary shares issuable upon exercise of the warrants, and the Company will use its commercially reasonable efforts to cause the same to become effective within 60 business days after the closing of the initial Business Combination, and to maintain the effectiveness of such registration statement and a current prospectus relating to those Class A ordinary shares until the warrants expire or are redeemed, as specified in the warrant agreement; provided that if the Company’s Class A ordinary shares are at the time of any exercise of a warrant not listed on a national securities exchange such that they satisfy the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at the Company’s option, require holders of public warrants who exercise their warrants to do so on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elects, the Company will not be required to file or maintain in effect a registration statement, and the Company will use its commercially reasonably efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. If a registration statement covering the Class A ordinary shares issuable upon exercise of the warrants is not effective by the 60th business day after the closing of the initial Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act or another exemption, and the Company will use its commercially reasonably efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. In such event, each holder would pay the exercise price by surrendering the warrants for that number of Class A ordinary shares equal to the quotient obtained by dividing (x) the product of the number of Class A ordinary shares underlying the warrants, multiplied by the excess of the “fair market value” (defined below) less the exercise price of the warrants by (y) the fair market value. The “fair market value” as used in this paragraph means the volume weighted average price of the Class A ordinary shares for the 10 trading days ending on the trading day prior to the date on which the notice of exercise is received by the warrant agent.

Redemption of warrants when the price per Class A ordinary share equals or exceeds $16.50. Once the warrants become exercisable, the Company may redeem the outstanding warrants:

● in whole and not in part;

● at a price of $0.01 per warrant;

20

Aimfinity Investment Corp. I
Notes To Unaudited Consolidated Financial Statements

● upon a minimum of 30 days’ prior written notice of redemption to each warrant holder; and

● if, and only if, the closing price of the Class A ordinary shares equals or exceeds $16.50 per share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant as described under the heading “-Warrants-Public Shareholders’ Warrants-Anti-dilution Adjustments”) for any 20 trading days within a 30-trading day period ending three trading days before the Company sends the notice of redemption to the warrant holders).

In addition, if (x) The Company issue additional Class A ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20 per ordinary share (with such issue price or effective issue price to be determined in good faith by the board of directors and, in the case of any such issuance to the Company’s sponsor or its affiliates, without taking into account any founder shares held by the Company’s sponsor or such affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of the consummation of the initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of the Company’s Class A ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates the initial Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price and the $16.50 per share redemption trigger price described above will be adjusted (to the nearest cent) to be equal to 165% of the higher of the Market Value and the Newly Issued Price.

Note 9 — Segment information

ASC Topic 280, “Segment Reporting,” establishes standards for companies to report in their financial statement information about operating segments, products, services, geographic areas, and major customers. Operating segments are defined as components of an enterprise for which separate financial information is available that is regularly evaluated by the Company’s chief operating decision maker, or group, in deciding how to allocate resources and assess performance. The Company has adopted the guidance in ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, in the accompanying unaudited consolidated financial statements using the retrospective method of adoption.

The Company’s chief operating decision maker has been identified as the Chief Executive Officer (“CODM”), who reviews the operating results for the Company as a whole to make decisions about allocating resources and assessing financial performance. Accordingly, management has determined that the Company only has one operating and reportable segment.

When evaluating the Company’s performance and making key decisions regarding resource allocation the CODM reviews several key metrics, which include the following:

		For the Three Months Ended June 30, 2025				For the Three Months Ended June 30, 2024				For the Six Months Ended June 30, 2025				For the Six Months Ended June 30, 2024
Legal and professional services costs		$	(114,898	)		$	(87,250	)		$	(251,342	)		$	(170,190	)
Other formation and operating costs			(17,367	)			(44,446	)			(158,174	)			(91,026	)
Total formation and operating costs			(132,265	)			(131,696	)			(409,516	)			(261,216	)
Interest earned on cash and investment held in Trust			142,759				570,206				484,941				1,138,590
Net income		$	10,494			$	438,510			$	75,425			$	877,374

21

Aimfinity Investment Corp. I
Notes To Unaudited Consolidated Financial Statements

The key measures of segment profit or loss reviewed by our CODM are interest earned on cash and investments held in Trust Account and formation and operating expenses. The CODM reviews the interest earned on cash and investment in Trust Account to measure and monitor shareholder value and determine the most effective strategy of cash and investment with the Trust Account funds while maintaining compliance with the trust agreement. Within formation and operating costs, the CODM specifically reviews professional service fees in connection with the business combination, which are a significant segment expense, and include legal fees, and advisory fees, as these represent significant costs affecting the Company’s consummation of the Business Combination. Other formation and operating costs, including accounting expenses, printing expenses, and regulatory filing fees, are reviewed in aggregate to ensure alignment with budget and contractual obligations. These expenses are monitored to manage and forecast cash available to complete a business combination within the required period.

Note 10 — Commitments and Contingencies

On May 27, 2025 (“Closing Date”), Aimfinity Investment Merger Sub I (“PubCo”), a wholly owned subsidiary of the Company, entered into a Securities Purchase Agreement (“SPA”) with I-Fa Chang, a related party to the Company, to acquire 100% of the equity interests in Inkrock Holding Limited (“Inkrock”), a British Virgin Islands company, by issuing 687,054 of its ordinary shares to I-Fa Chang as purchase consideration in exchange for 50,000 Inkrock shares. The closing date shall occur contemporaneously upon the completion of the business combination. This agreement share termination on the earlier of i) merger agreement is terminated and ii) the last day by which the Company must complete a business combination which is presently October 28, 2025. Upon the execution of the agreement, the PubCo had issued 687,054 of its ordinary shares to I-Fa Chang, however, the 50,000 share of Inkrock shares were not transfer to PubCo yet. Inkrock owns real property located in Mercer Island, Washington, which is subject to an outstanding mortgage balance of approximately $1.4 million. On October 6, 2025, PubCo, Inkrock and I-Fa Chang entered into a termination agreement related to above SPA. (see Note 11)

Note 11 — Subsequent Events

The Company evaluated subsequent events and transactions that occurred after the balance sheet date through the date when the unaudited consolidated financial statements were issued. Based on this review, management identified the following subsequent events that are required disclosure in the unaudited consolidated financial statements.

On July 25, 2025, Pubco and Horn Enterprise entered into a stock purchase agreement with each of Ji-Jung Chou, a Taiwanese national, and Shi-Jyun Lan, a Taiwanese national (together with Ji-Jung Chou, the “Horn PIPE Investors”), pursuant to each of which, each Horn PIPE Investor agreed to purchase from Pubco such number of ordinary shares of Pubco, par value $0.0001 per share (the “Purchaser Shares”), equal to the outstanding principal amount of a non-interest bearing loan of $45,000,000 New Taiwanese Dollar (or approximately $1,536,413) Horn borrowed from such PIPE Investor, divided by $10.00, immediately prior to or at the closing of the Business Combination.  The PIPE Investors shall accept the Purchaser Shares as satisfaction of the payment of their loans in lieu of repayment of loans by Horn in cash.

On October 6, 2025, PubCo, Inkrock and I-Fa Chang entered into a termination agreement, pursuant to which Mr. Chang agreed to surrender and forefeit 687,054 ordinary shares issued by the PubCo, and the parties agreed to otherwise terminate the agreement and release each of the parties from any further obligations under the SPA. In its place, On October 7, 2025, PubCo, Inkrock and Mr. Chang entered into a Securities Purchase Agreement, pursuant to which PubCo will acquire 100% of the equity interests in Inkrock from Mr. Chang and will issue 687,054 of its ordinary shares to Mr. Chang as purchase consideration, upon closing of the Business Combination.

Promissory Notes

From July to September 2025, $167,471 have been deposited into the Trust Account for the Public Shareholders, resulting in one extension of the period of time Aimfinity has to consummate the initial business combination by October 28, 2025.

22

ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

References in this report (the “Quarterly Report”) to “we,” “us” or the “Company” refer to Aimfinity Investment Corp. I. References to our “management” or our “management team” refer to our officers and directors, and references to the “Sponsor” refer to Aimfinity Investment, LLC. The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with the unaudited financial statements and the notes thereto contained elsewhere in this Quarterly Report. Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties.

Special Note Regarding Forward-Looking Statements

This Quarterly Report includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) that are not historical facts, and involve risks and uncertainties that could cause actual results to differ materially from those expected and projected. All statements, other than statements of historical fact included in this Quarterly Report including, without limitation, statements in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” regarding the Company’s financial position, business strategy and the plans and objectives of management for future operations, are forward-looking statements. Words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and variations thereof and similar words and expressions are intended to identify such forward-looking statements. Such forward- looking statements relate to future events or future performance, but reflect management’s current beliefs, based on information currently available. A number of factors could cause actual events, performance or results to differ materially from the events, performance and results discussed in the forward-looking statements. For information identifying important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the Risk Factors section of the Company’s final prospectus for its initial public offering (the “IPO” described below) filed with the Securities Exchange Commission (the “SEC”) on April 26, 2022 (File No. 333-263874) (the “Prospectus”). The Company’s securities filings can be accessed on the EDGAR section of the SEC’s website at www.sec.gov. Except as expressly required by applicable securities law, the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Overview

We are a blank check company incorporated on July 26, 2021 (inception) as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities (the “Initial Business Combination”). We intend to effectuate our Initial Business Combination using cash from the proceeds of our IPO and the sale of our shares, debt or a combination of cash, equity and debt. We expect to continue to incur significant costs in the pursuit of our acquisition plans. We cannot assure you that our plans to complete an Initial Business Combination will be successful.

Our Initial Public Offering

On April 28, 2022, Aimfinity consummated its IPO of 8,050,000 units, which included 1,050,000 Public Units issued pursuant to the full exercise by the underwriters of their over-allotment option, with each Public Unit consisting of one AIMA Class A Ordinary Share, one AIMA Class 1 Warrants and one-half of one AIMA Class 2 Warrants, with each whole AIMA Class 1 or Class 2 Warrant entitling the holder thereof to purchase one AIMA Class A Ordinary Share for $11.50 per share. The Public Units were sold at a price of $10.00 per Unit, and the IPO generated gross proceeds of $80,500,000. Simultaneously with the closing of the IPO, Aimfinity consummated a Private Placement with the Sponsor of an aggregate of 492,000 Private Placement Units (including 42,000 Private Placement Units purchased pursuant to the full exercise by the underwriters of their over-allotment option) at a price of $10.00 per Private Placement Unit, generating gross proceeds to Aimfinity of $4,920,000. Each Private Placement Unit consists of one AIMA Class A Ordinary Share, one AIMA Class 1 Warrant, and one-half of one AIMA Class 2 Warrant. The terms and provisions of the Private Placement Warrants are identical to the Public Warrants, except that, subject to certain limited exceptions, they are subject to transfer restrictions until 30 days following the consummation of the Company’s initial business combination. On April 28, 2022, a total of $82,110,000 of the net proceeds from the IPO and the Private Placement was deposited in the Trust Account established for the benefit of Aimfinity’s Public Shareholders at a U.S. based Trust Account, with U.S. Bank, National Association, acting as trustee.

23

The AIMA Class 1 Warrants and AIMA Class 2 Warrants have similar terms, except that the AIMA Class 1 Warrants separated and began separate trading on June 16, 2022 (the 52^nd day following the effective date of the IPO). Holders have the option to continue to hold the Public Units or separate the AIMA Class 1 Warrants from the Public Units. Separation of the Class 1 Warrants from the Public Units will result in new units consisting of one AIMA Class A Ordinary Share and one-half of one AIMA Class 2 Warrant. Holders will need to have their brokers contact the Company’s transfer agent in order to separate the Public Units into AIMA Class 1 Warrants and AIMA New Units consisting of one AIMA Class A Ordinary Share and one-half of one AIMA Class 2 Warrant. Additionally, the Public Units and the AIMA New Units will automatically separate into their component parts and will not be traded after completion of the initial business combination.

Since Aimfinity’s IPO, its sole business activity has been identifying, evaluating suitable acquisition transaction candidates and preparing for consummation of an initial business combination. It presently has no revenue and have had losses since inception from incurring formation and operating costs. It has relied upon the sale of Aimfinity securities and loans from the Sponsor and other parties to fund its operations.

Business Combination with Docter Inc.

On October 13, 2023, Aimfinity entered into that certain Agreement and Plan of Merger (as may be amended, supplemented or otherwise modified from time to time, the “Merger Agreement”), by and between Aimfinity, Docter Inc., a Delaware corporation (the “Target”), Aimfinity Investment Merger Sub I, a Cayman Islands exempted company and a newly formed wholly-owned subsidiary of Aimfinity (“PubCo”), and Aimfinity Investment Merger Sub II, Inc., a Delaware corporation and wholly-owned subsidiary of PubCo (“Merger Sub”), pursuant to which (a) Aimfinity will be merged with and into PubCo (the “Reincorporation Merger”), with PubCo surviving the Reincorporation Merger, and (b) Merger Sub will be merged with and into the Docter (the “Acquisition Merger”), with Docter surviving the Acquisition Merger as a direct wholly owned subsidiary of PubCo (all transactions contemplated under the Merger Agreement, collectively, the “Business Combination”). Following the consummation of the Business Combination (the “Closing”), PubCo will be a publicly traded company.

At the effective time of the Reincorporation Merger (the “Reincorporation Merger Effective Time”), (i) each of the issued and outstanding AIMA Units will automatically separate into one AIMA Class 1 Warrant and one AIMA New Unit, (ii) upon separation of the AIMA Units, each of the issued and outstanding AIMA New Unit (except the AIMA New Units containing the redeemed AIMA Class A Ordinary Share and corresponding forfeited AIMA Class 2 Warrant) will automatically separate into one AIMA Class A Ordinary Share and one-half of one AIMA Class 2 Warrant, (iii) each of the issued and outstanding AIMA Ordinary Share will be converted automatically into one PubCo Ordinary Share, and (iv) each of the issued and outstanding AIMA Warrant shall be converted automatically into one PubCo Warrant. Each of the issued and outstanding security will automatically be cancelled and cease in existence and trading with respect to Aimfinity’s security and converted into applicable security of PubCo except as provided in the Merger Agreement or under operation of law.

At the effective time of the Acquisition Merger (the “Effective Time”), which shall take place one business after the Reincorporation Merger Effective Time, by virtue of the Acquisition Merger and without any action on the part of us, PubCo, Merger Sub, Docter or the Docter Stockholders immediately prior to the Effective Time, each Docter Stockholder’s shares of Docter Stock issued and outstanding immediately prior to the Effective Time (except certain excluded shares) will be cancelled and automatically converted into the right to receive, without interest, the applicable portion of the Closing Payment Shares as set forth in the Closing Consideration Spreadsheet (as defined in the Merger Agreement) on a pro rata basis based on the number of Target Shares held by them as of immediately prior to the Effective Time.

Up to an additional 2,500,000 PubCo Ordinary Shares may be issued to the Docter Stockholders as contingent post-closing earnout consideration. The Earnout Shares will not be issued until as below:

● 1,000,000 Earnout Shares will be issued to each Docter Stockholder on a pro rata basis if and only if PubCo completes sales of at least 30,000 Devices (as defined in the Merger Agreement) during fiscal year 2024 as reflected in its audited consolidated annual financial statements for the fiscal year ending December 31, 2024 prepared in accordance with the U.S. GAAP as filed with the SEC;

● 1,500,000 Earnout Shares will be issued to each Docter Stockholder on a pro rata basis if and only if PubCo completes sales of at least 40,000 Devices during fiscal year 2025 as reflected in its audited consolidated annual financial statements for the fiscal year ending December 31, 2025 prepared in accordance with the U.S. GAAP as filed with the SEC.

24

On June 5, 2024, Aimfinity, Pubco, Merger Sub and Docter entered into an amendment to the Merger Agreement (the “Amendment No. 1”) to modify the composition of PubCo ’s board of directors upon and immediately following the completion of the Business Combination.

Before Amendment No. 1 was adopted, the Merger Agreement provided that, upon and immediately following the closing of the Business Combination, PubCo’s board of directors shall consist of five (5) directors, among which four (4) directors will be designated by Aimfinity Investment LLC, the sponsor of the AIMA’s initial public offering (the “Sponsor”), until the second general meeting of shareholders of PubCo, and one (1) director will be designated by Docter until the first general meeting of shareholders of PubCo

Pursuant to the Amendment No. 1, upon and immediately following the closing of the Business Combination, PubCo’s board of directors shall consist of five (5) directors, among which three (3) directors will be designated by Docter until the first general meeting of shareholders of PubCo, and two (2) directors will be designated by the Sponsor until the second general meeting of shareholders of PubCo.

On January 29, 2025, Aimfinity, Pubco, Merger Sub and Docter entered into an amendment to the Merger Agreement (the “Amendment No. 2”) to modify the earnout arrangement as follows:

● 1,000,000 Earnout Shares will be issued to each Docter Stockholder on a pro rata basis if and only if PubCo completes sales of at least 30,000 Devices (as defined in the Merger Agreement) during fiscal year 2025 as reflected in its audited consolidated annual financial statements for the fiscal year ending December 31, 2025 prepared in accordance with the U.S. GAAP as filed with the SEC;

● 1,500,000 Earnout Shares will be issued to each Docter Stockholder on a pro rata basis if and only if PubCo completes sales of at least 40,000 Devices during fiscal year 2026 as reflected in its audited consolidated annual financial statements for the fiscal year ending December 31, 2026 prepared in accordance with the U.S. GAAP as filed with the SEC.

Extensions

Following the closing of the IPO, under the Company’s then-effective amended and restated memorandum and articles of association, the Company would have until July 28, 2023 (or January 28, 2024 if the Company extends the period of time to consummate an initial business combination) to consummate an initial business combination. On July 27, 2023, the Company held an extraordinary general meeting of shareholders (the “First EGM”). At the First EGM, the shareholders of the Company, by special resolution, approved the proposal to amend the Company’s then effective amended and restated memorandum and articles of association (the “First Charter Amendment”) to (i) allow the Company until July 28, 2023 to consummate an initial business combination, and to (ii) elect to extend the period (the “Combination Deadline”) to consummate an initial business combination up to nine times, each by an additional one-month period, for a total of up to nine months to April 28, 2024, by depositing to the Company’s Trust Account the amount lesser of (i) $85,000 for each one-month extension or (ii) $0.04 for each Public Share for each one-month extension (the “First Charter Amendment Proposal”). Under Cayman Islands law, the First Charter Amendment took effect upon approval of the First Charter Amendment Proposal by the shareholders at the First EGM. Pursuant to the First Charter Amendment, a total of 9 one-month extensions, each in the amount of $85,000 (each, a “First Charter Amendment Monthly Extension”), were sought by the Company, with a total of $765,000 deposited by the Sponsor or its designee to the Trust Account, extending the Combination Deadline from July 28, 2023 to April 28, 2024.

In connection with the First EGM, the AIMA Public Shareholders were afforded with an opportunity to redeem their AIMA Public Shares. In connection with the redemptions, 4,076,118 AIMA New Units, or about 50.9% of the AIMA New Units issued and outstanding at the time, were submitted for redemption and the components thereof, including the Public Shares and the AIMA Class 2 Warrants thereof, were cancelled.

On April 23, 2024, the Company held a second extraordinary general meeting of shareholders (the “Second EGM”). At the Second EGM, the shareholders of the Company, by special resolution, approved the proposal to amend the Company’s then-effective amended and restated memorandum and articles of association (the “Second Charter Amendment”) to (i) allow the Company until April 28, 2024 to consummate an initial business combination, and to (ii) elect to extend the Combination Deadline up to nine times, each by an additional one-month period (each a “Second Charter Amendment Monthly Extension”), for a total of up to nine months to January 28, 2025, by depositing to the Company’s Trust Account the amount lesser of (i) $60,000 for each one-month extension or (ii) $0.035 for each Public Share for each one-month extension (the “Second Charter Amendment Monthly Extension”). Under Cayman Islands law, the Second Charter Amendment took effect upon approval of the Second Charter Amendment Proposal by the shareholders at the Second EGM. Pursuant to the Second Charter Amendment, a total of 9 one-month extensions, each in the amount of $60,000 (each, a “First Charter Amendment Monthly Extension”), were sought by the Company, with a total of $540,000 deposited by the Sponsor or its designee to the Trust Account, extending the Combination Deadline from April 28, 2025 to January 28, 2025.

25

In connection with the Second EGM, the AIMA Public Shareholders were afforded with an additional opportunity to redeem their AIMA Public Shares. 860,884 AIMA New Units, or about 21.7% of the AIMA New Units issued and outstanding at the time, were submitted for redemption and the components thereof, including the Public Shares and the AIMA Class 2 Warrants thereof, were cancelled. As a result, an aggregate of approximately $9,684,945 were distributed from the Trust Account to the redeeming Public Shareholders.

On January 9, 2025, the Company held a third extraordinary general meeting of shareholders (the “Third EGM”). At the Third EGM, the shareholders of the Company, by special resolution, approved the proposal to amend the Company’s then-effective amended and restated memorandum and articles of association (the “Third Charter Amendment”) to (i) allow the Company until January 28, 2025 to consummate an initial business combination, and to (ii) elect to extend the Combination Deadline up to nine times, each by an additional one-month period (each a “Third Charter Amendment Monthly Extension”), for a total of up to nine months to October 28, 2025, by depositing to the Company’s Trust Account the amount of $0.05 for each Public Share for each one-month extension (the “Third Charter Amendment Monthly Extension”). Under Cayman Islands law, the Third Charter Amendment took effect upon approval of the Third Charter Amendment Proposal by the shareholders at the Third EGM. No Third Charter Amendment Monthly Extension has been sought as of the date hereof.

In connection with the Third EGM, the AIMA Public Shareholders were afforded with an additional opportunity to redeem their AIMA Public Shares. As a result, 1,996,522 AIMA New Units, or about 64.2% of the public AIMA New Units issued and outstanding at the time, were submitted for redemption and the components thereof, including the Public Shares and the AIMA Class 2 Warrants thereof, were cancelled. As a result, an aggregate of approximately $23,778,577 were distributed from the Trust Account to the redeeming Public Shareholders. In connection with the Current Monthly Extensions, as of the date hereof, nine Current Monthly Extension Payment in the aggregate amount of $502,414 have been deposited into the Trust Account, allowing Aimfinity to extend the Combination Period until October 28, 2025.

As of the date hereof, the Company made nine payments for First Charter Amendment Monthly Extensions, nine payments for Second Charter Amendment Monthly Extensions, and nine payment for the Current Monthly Extension Payment into Trust Account for the Public Shareholders, resulting in an extension of the Combination Deadline to October 28, 2025.

For each payment in connection with the First Charter Amendment Monthly Extensions, the Second Charter Amendment Monthly Extensions, or the Current Monthly Extensions, on the date such payment was deposited to the Company’s Trust Account, we issued an unsecured promissory note to I-Fa Chang to evidence the payments made by him for the deposit of such payment (in the amount of $85,000, $60,000 or $55,824), as the case may be (in each case, a “Monthly Extension Note”).

Each of such Monthly Extension Notes have the same terms, except with regard to the amount. Each note bears no interest and is payable in full upon the earlier to occur of (i) the consummation of the Company’s Initial Business Combination or (ii) the date of expiry of the term of the Company (the “Maturity Date”). The following shall constitute an event of default: (i) a failure to pay the principal within five business days of the Maturity Date; (ii) the commencement of a voluntary or involuntary bankruptcy action, (iii) the breach of the Company’s obligations thereunder; (iv) any cross defaults; (v) an enforcement proceedings against the Company; and (vi) any unlawfulness and invalidity in connection with the performance of the obligations thereunder, in which case such Monthly Extension Note may be accelerated.

The payee of each Monthly Extension Note, I-Fa Chang, has the right, but not the obligation, to convert each Monthly Extension Note, in whole or in part, respectively, into Private Placement Units of the Company, that are identical to the Private Placement Units issued by the Company in the Private Placement consummated simultaneously with the Company’s IPO, subject to certain exceptions, as described in the Prospectus, by providing the Company with written notice of the intention to convert at least two business days prior to the closing of the Initial Business Combination. The number of Private Placement Units to be received by I-Fa Chang in connection with such conversion shall be an amount determined by dividing (x) the sum of the outstanding principal amount payable to the Sponsor by (y) $10.00.

26

The issuance of the Monthly Extension Notes were made pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act of 1933, as amended.

As of the date hereof, the Company has issued three promissory notes (the “Working Capital Notes”) to Mr. Chang (the manager and designee of the sponsor of the Company): one on December 8, 2023, for up to $500,000, to be used for a portion of the Company’s working capital, one on April 8, 2024, for up to $500,000, to be used for a portion of the Company’s working capital, and one on October 21, 2024, for up to $1,500,000, to be used for a portion of the Company’s working capital. As of June 30, 2025, an aggregate of $1,420,799 of working capital loans have been provided by Mr. Chang under the Working Capital Notes, and it is expected that further working capital loans may be provided by Mr. Chang under the Working Capital Notes before the closing of the Docter Business Combination.

Pursuant to the Merger Agreement, up to $1,500,000 of Working Capital Notes or Monthly Extension Notes may be converted into private units of the Company, each of which is the same as the private placement units sold in the private sales consummated simultaneously with the initial public offering of the Company.

Pursuant to a certain exchange agreement, dated April 8, 2025, by and among the Company, Mr. Chang and certain other parties to the Merger Agreement, upon the closing of the Business Combination by and between the Company and Docter, all $1,472,471 under the Monthly Extension Notes outstanding and $27,529 under the Working Capital Notes outstanding converted into 150,000 Private Units of the Company, and the remaining balance of the Working Capital Notes, including any working capital loans that may be provided prior to the closing of the Business Combination, and any additional Monthly Extension Notes outstanding, less $27,529, will be exchanged for such number of Purchaser ordinary shares, par value $0.0001 per share (“Purchaser ordinary shares”), at a conversion price of $10.00 per share.

Transaction Financing

On April 8, 2025, Pubco, Docter, and Horn Enterprise Co., Ltd. (“Horn Enterprise”), the wholly-owned subsidiary of Docter, entered into two separate exchange agreements (the “Docter Exchange Agreements”) with Mr. Hsin-Ming Huang, CEO of Docter and Horn Enterprise, and Ms. Yi-Jun Ye, a Taiwanese national, respectively, each of which had previously loaned funds to Docter and/or Horn (the “Docter Note Holders”), pursuant to which the Docter Note Holders agree to convert all outstanding principal and interest of loans owed by Docter or Horn Enterprise as of the closing of the Business Combination into such number of PubCo Ordinary Shares at a conversion price of $10.00 per share.

Also on April 8, the Company, Pubco, Docter, and Mr. Chang, as the holder of certain Working Capital Notes and the Monthly Extension Notes, entered into an exchange agreement (the “AIMUF Exchange Agreement”), dated April 8, 2025, by and among the (as defined therein), all $1,472,471 under the Extension Notes and $27,529 under the Working Capital Notes will be converted into 150,000 private placement units of AIMUF, and the remaining balance of the Working Capital Notes, including any working capital loans that may be provided prior to the closing of the Business Combination, and any additional Monthly Extension Notes outstanding, less $27,529, will be exchanged for such number of PubCo Ordinary Shares at a conversion price of $10.00 per share.

Pursuant to a certain securities purchase agreement, dated May 27, 2025, by and between Pubco and I-Fa Chang, the Company’s related party, and Inkrock Holding Limited, a British Virgin Islands company, Pubco issued 687,054 ordinary shares, par value $0.0001 per share to I-Fa Chang in exchange for acquiring the control of Inkrock Holding Limited from I-Fa Chang upon consummation of the Business Combination. Inkrock Holding Limited owns a real property located in Mercer Island, Washington State.

On October 6, 2025, PubCo, Inkrock and I-Fa Chang entered into a termination agreement, pursuant to which Mr. Chang agreed to surrender and forefeit 687,054 ordinary shares issued by the PubCo, and the parties agreed to otherwise terminate the agreement and release each of the parties from any further obligations under the SPA. In its place, On October 7, 2025, PubCo, Inkrock and Mr. Chang entered into a Securities Purchase Agreement, pursuant to which PubCo will acquire 100% of the equity interests in Inkrock from Mr. Chang and will issue 687,054 of its ordinary shares to Mr. Chang as purchase consideration, upon closing of the Business Combination.

On July 25, 2025, Pubco and Horn Enterprise entered into a stock purchase agreement with each of Ji-Jung Chou, a Taiwanese national, and Shi-Jyun Lan, a Taiwanese national (together with Ji-Jung Chou, the “Horn PIPE Investors”), pursuant to each of which, each Horn PIPE Investor agreed to purchase from Pubco such number of ordinary shares of Pubco, par value $0.0001 per share (the “Purchaser Shares”), equal to the outstanding principal amount of a non-interest bearing loan of $45,000,000 New Taiwanese Dollar (or approximately $1,536,413) Horn borrowed from such PIPE Investor, divided by $10.00, immediately prior to or at the closing of the Business Combination.  The PIPE Investors shall accept the Purchaser Shares as satisfaction of the payment of their loans in lieu of repayment of loans by Horn in cash.

27

Discharge Agreements

On June 13, 2025, the Company, Pubco, Merger Sub, and Docter entered into agreements for the satisfaction and discharge of indebtedness (each a “Discharge Agreement”, together, the “Discharge Agreements”) with D. Boral Capital LLC (f/k/a EF Hutton LLC, division of Benchmark Investments, LLC, “D. Boral”) and US Tiger Securities, Inc. (“US Tiger”), respectively. D. Boral and US Tiger were the underwriters (collectively, the “Underwriters”) of the initial public offering of AIMUF (“IPO”) and the Discharge Agreements have identical terms and conditions. Pursuant to the Discharge Agreements, in lieu of payment of the deferred underwriting commission of $2,817,500 (“Deferred Commission”), each of D. Boral and US Tiger will accept (1) $80,000 in cash at Closing; and (2) 132,875 Purchaser Ordinary Shares at Closing, subject to any adjustments as provided in the Discharge Agreement.

Results of Operations

We have neither engaged in any operations nor generated any revenues to date. Our only activities from July 26, 2021 (inception) to June 30, 2025 were organizational activities, those necessary to prepare for the IPO, described below, and, after the IPO, identifying a target company for an Initial Business Combination. We do not expect to generate any operating revenues until after the completion of our Initial Business Combination. We may generate non-operating income in the form of interest income on marketable securities held in the Trust Account. We incur expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance), as well as for due diligence expenses in connection with completing an Initial Business Combination.

For the three months ended June 30, 2025, we had a net income of $10,494 which consisted of interest income of $142,759 on cash and investments held in Trust Account which was offset by operating cost of $132,265.

For the three months ended June 30, 2024, we had a net income of $438,510 which consisted of interest income of $570,206 on cash and investments held in Trust Account which was offset by operating cost of $131,696.

For the six months ended June 30, 2025, we had a net income of $75,425 which consisted of interest income of $484,941 on cash and investments held in Trust Account which was offset by operating cost of $409,516.

For the six months ended June 30, 2024, we had a net income of $877,374 which consisted of interest income of $1,138,590 on cash and investments held in Trust Account which was offset by operating cost of $261,216.

Liquidity and Capital Resources

Until the consummation of the IPO, our only source of liquidity was an initial purchase of ordinary shares by the Sponsor and loans from our Sponsor.

Following the closing of the IPO and sale of the Private Placement Units on April 28, 2022, a total of $82,110,000 was placed in the Trust Account, and we had $1,495,650 of cash held outside of the Trust Account, after payment of costs related to the IPO, and available for working capital purposes. In connection with the IPO, we incurred $5,117,607 in transaction costs, consisting of $1,610,000 of underwriting fees, $2,817,500 of deferred underwriting fees and $690,107 of other offering costs.

As of June 30, 2025, $13,981,534 was held in the Trust Account in money market funds, which are invested in U.S. Treasury Securities. We intend to use substantially all of the funds held in the Trust Account, including any amounts representing interest earned on the Trust Account, excluding deferred underwriting commissions, to complete our Initial Business Combination. We may withdraw interest from the Trust Account to pay taxes, if any. To the extent that our share capital or debt is used, in whole or in part, as consideration to complete an Initial Business Combination, the remaining proceeds held in the Trust Account will be used as working capital to finance the operations of the target business or businesses, make other acquisitions and pursue our growth strategies.

Aimfinity intends to use the funds held outside the Trust Account to primarily identify and evaluate target businesses, perform business due diligence on prospective target businesses, travel to and from the offices, plants or similar locations of prospective target businesses or their representatives or owners, review corporate documents and material agreements of prospective target businesses, structure, negotiate and complete an initial business combination.

In order to fund working capital deficiencies or finance transaction costs in connection with an initial business combination, the Sponsor or an affiliate of the Sponsor or certain of Aimfinity’s officers and directors may, but are not obligated to, loan us funds as may be required.

28

On December 8, 2023, the Company issued a promissory note to I-Fa Chang, as the designee, sole member and manager of the Sponsor, under which I-Fa Chang agreed to loan the Company up to $500,000 to be used for a portion of the working capital. This loan is non-interest bearing, unsecured and is due at the earlier of (1) the date on which the Company consummates its initial business combination or (2) the date on which the Company liquidates and dissolves. I-Fa Chang, as the payee, has the right, but not the obligation, to convert the note, in whole or in part, into Private Placement Units of the Company, that are identical to the Private Placement Units issued by the Company in the Private Placement consummated simultaneously with the Company’s IPO, subject to certain exceptions, as described in the IPO Prospectus, by providing the Company with written notice of the intention to convert at least two business days prior to the closing of the Initial Business Combination. The number of Private Placement Units to be received by I-Fa Chang in connection with such conversion shall be an amount determined by dividing (x) the sum of the outstanding principal amount payable to I-Fa Chang by (y) $10.00.

On April 4, 2024, the Company issued a promissory note to I-Fa Chang, as the designee, sole member and manager of the Sponsor, under which I-Fa Chang agreed to loan the Company up to $500,000 to be used for a portion of the working capital. This loan is non-interest bearing, unsecured and is due at the earlier of (1) the date on which the Company consummates its initial business combination or (2) the date on which the Company liquidates and dissolves. I-Fa Chang, as the payee, has the right, but not the obligation, to convert the note, in whole or in part, into Private Placement Units of the Company, that are identical to the Private Placement Units issued by the Company in the Private Placement consummated simultaneously with the Company’s IPO, subject to certain exceptions, as described in the IPO Prospectus, by providing the Company with written notice of the intention to convert at least two business days prior to the closing of the Initial Business Combination. The number of Private Placement Units to be received by I-Fa Chang in connection with such conversion shall be an amount determined by dividing (x) the sum of the outstanding principal amount payable to I-Fa Chang by (y) $10.00.

As of June 30, 2025, the Company, had $1,393,270 borrowings under the working capital loans.

As of June 30, 2025, the Company had cash of $4,895 and a working capital deficiency of $2,515,028.

In addition, in order to finance transaction costs in connection with an initial business combination, the Company’s Sponsor or an affiliate of the Sponsor or certain of the Aimfinity’s officers and directors have been provided the Company working capital loans (the “Working Capital Loans”). As of June 30, 2025, there were $1,393,270 under Working Capital Loans.

In connection with the Company’s assessment of going concern considerations in accordance with Financial Accounting Standard Board’s Accounting Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” management has determined that these conditions raise substantial doubt about the Company’s ability to continue as a going concern. In addition, if the Company is unable to complete an initial business combination by the Combination Deadline, the Company’s board of directors would proceed to commence a voluntary liquidation and thereby a formal dissolution of the Company. There is no assurance that the Company’s plans to consummate an initial business combination will be successful by the Combination Deadline. As a result, management has determined that such additional conditions also raise substantial doubt about the Company’s ability to continue as a going concern. The financial statement does not include any adjustments that might result from the outcome of this uncertainty. 

Off-Balance Sheet Financing Arrangements

We have no obligations, assets or liabilities, which would be considered off-balance sheet arrangements as of June 30, 2025. We do not participate in transactions that create relationships with unconsolidated entities or financial partnerships, often referred to as variable interest entities, which would have been established for the purpose of facilitating off-balance sheet arrangements. We have not entered into any off-balance sheet financing arrangements, established any special purpose entities, guaranteed any debt or commitments of other entities, or purchased any non-financial assets.

29

Contractual Obligations

Registration Rights

The holders of the founder shares, Private Placement Units and Private Warrants, including any of those issued upon conversion of Working Capital Loans (and any Private Placement Units issuable upon the exercise of the Private Warrants that may be issued upon conversion of Working Capital Loans) will be entitled to registration rights pursuant to a registration and shareholder rights agreement signed on April 25, 2022. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed after the completion of our Initial Business Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. The Company will bear the costs and expenses of filing any such registration statements.

Underwriting Agreement

We granted the underwriters a 45-day option from the date of the IPO to purchase up to 1,050,000 additional Public Units to cover over- allotments, if any, at the IPO price less the underwriting discounts and commissions. The underwriters exercised the over-allotment option in full on April 27, 2022.

The underwriters received a cash underwriting discount of $0.20 per Public Unit, or $1,610,000 in the aggregate and paid at the closing of the IPO. In addition, the underwriters will be entitled to a deferred fee of $0.35 per Public Unit, or approximately $2,817,500 in the aggregate upon the consummation of an initial business combination. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes its initial Business Combination, subject to the terms of the underwriting agreement.

Critical Accounting Policies

The accompanying unaudited financial statements are presented in conformity with GAAP and pursuant to the rules and regulations of the SEC.

Recent Accounting Pronouncements

On November 4, 2024, the FASB issued ASU No. 2024-03, Expense Disaggregation Disclosures (“ASU 2024-03”). ASU 2024-03 amends ASC 220, Comprehensive Income to expand income statement expense disclosures and require disclosure in the notes to the financial statements of specified information about certain costs and expenses. ASU 2024-03 is required to be adopted for fiscal years commencing after December 15, 2026, with early adoption permitted. The Company is currently evaluating the impact of adopting the standard on the Company’s unaudited consolidated financial statements.

Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this item.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and General Counsel, to allow timely decisions regarding required disclosure.

As required by Rules 13a-15f and 15d-15 under the Exchange Act, our Chief Executive Officer and General Counsel carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of June 30, 2025. Based upon their evaluation, our Chief Executive Officer and General Counsel concluded that our disclosure controls and procedures (as defined in Rules 13a-15 (e) and 15d-15 (e) under the Exchange Act) were not effective.

Changes in Internal Control Over Financial Reporting

During the period covered by this Quarterly Report on Form 10-Q, there has been no change in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

30

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

None.

ITEM 1A. RISK FACTORS.

As a smaller reporting company, we are not required to include risk factors in this Report. However, factors that could cause our actual results to differ materially from those in this Quarterly Report are any of the risks described in our Prospectus, our annual report on Form 10-K for the fiscal year ended December 31, 2024 (the “Annual Report”) as filed with the SEC on April 15, 2025, and in a definitive proxy statement/final prospectus in connection with the Docter Business Combination filed with the SEC on March 6, 2025 (File No. 333-284658). Any of these factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations. As of the date of this Quarterly Report, there have been no material changes to the risk factors disclosed in our Prospectus and Annual Report.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS FROM REGISTERED SECURITIES.

On December 4, 2021, the Sponsor acquired 2,875,000 Class B ordinary Shares for an aggregate purchase price of $25,000. The issuance of such founder shares to the Sponsor was made pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act. On March 18, 2022, our Sponsor surrendered to us for cancellation 862,500 Class B ordinary shares for no consideration, resulting in our Sponsor holding an aggregate of 2,012,500 Class B ordinary shares.

On April 28, 2022, we consummated the IPO of 8,050,000 Public Units, inclusive of 1,050,000 Public Units sold to the underwriters upon the underwriters’ election to partially exercise their over-allotment option. The Public Units were sold at a price of $10.00 per Public Unit, generating gross proceeds of $80,500,000. US Tiger Securities, Inc. and EF Hutton, division of Benchmark Investments, LLC acted as the joint book-running managers. The securities sold in the offering were registered under the Securities Act on a registration statement on Form S-1 (File No. 333-263874). The registration statement became effective on April 25, 2022.

Substantially concurrently with the closing of the IPO, the Company completed the private placement of 492,000 Private Placement Units to the Sponsor at a purchase price of $10.00 per Private Placement Unit, generating gross proceeds to the Company of $4,920,000.

The units sold as part of the Private Placement Units are identical to the units sold as part of the Public Units in the IPO, except that the Sponsor has agreed not to transfer, assign or sell any of the Private Placement Units (except to certain permitted transferees) until 30 days after the completion of the Company’s initial Business Combination. The issuance of the Private Placement Units was made pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act.

A total of $82,110,000 comprised of $80,850,000 of the proceeds from the IPO, and $3,220,000 of the proceeds from the Private Placement, were placed in a U.S.-based trust account maintained by U.S. Bank, National Association, acting as trustee.

We paid a total of $1,610,000 in underwriting discounts and commissions and $690,107 for other costs and expenses related to the IPO, including the Public Units issued pursuant to the partial exercise of the underwriters’ over-allotment option.

For a description of the use of the proceeds generated in our IPO and the Private Placement, see Part I, Item 2 of this Quarterly Report on Form 10-Q.

On March 17, 2023, the sponsor initiated a distribution of 280,000 founder shares and 492,000 Private Placement Units of the Company held by the Sponsor to Imperii Strategies LLC, Aimfinity Investment & Co., and Yuming Investments LLC, all existing members of the Sponsor at that time, and entered into a repurchase agreement with Xin Wang, Joshua Gordon, James J. Long and Nicholas Torres III, then directors and officers of the Company, to transfer 10,000 founder shares each to the Sponsor, as a result of which, the Sponsor directly held 1,692,500 founder shares as of March 17, 2023. The sale and repurchase of the founder shares and the distributions were made pursuant to an exemption from registration contained in Section 4(a)(2) of the Securities Act.

31

On January 19, 2024, pursuant to certain membership interest purchase and transfer agreement, Mr. Chang sold 2.954% of the Membership Interests of the Sponsor he held, which entitles the holder to receive distribution of 50,000 founder shares currently held under the Sponsor, to Mr. Chun-Cheng Su, a Taiwanese citizen, for 10,000,000 New Taiwan Dollar (approximately USD 319,000 as of the date thereof).  On the same date, pursuant to certain membership interest purchase and transfer agreement, Mr. Chang also sold 5.908% of the Membership Interests of the Sponsor he held, which entitles the holder to receive distribution of 100,000 founder shares currently held under the Sponsor, to Mr. Xuedong (Tony) Tian, our CFO and director, for USD1,243. The sale and repurchase of the membership interests were made pursuant to exemptions from registration contained in Section 4(a)(2) of the Securities Act.

As of the date hereof, the Company has issued three promissory notes (the “Working Capital Notes”) to Mr. I-Fa Chang (the manager and designee of the sponsor of the Company): one on December 8, 2023, for up to $500,000, to be used for a portion of the Company’s working capital, one on April 8, 2024, for up to $500,000, to be used for a portion of the Company’s working capital, and one on October 21, 2024, for up to $1,500,000, to be used for a portion of the Company’s working capital. As of March 31, 2025, an aggregate of $1,318,175 of working capital loans have been provided by Mr. Chang under the Working Capital Notes, and it is expected that further working capital loans may be provided by Mr. Chang under the Working Capital Notes before the closing of the Business Combination.

In addition, as of the date hereof, the Company has issued: (x) 9 promissory notes, from July 2023 to March 2024, each issued to Mr. Chang in the amount of $85,000 (collectively, the “First EGM Extension Notes”), pursuant to which Mr. Chang deposited $85,000 for each month to the trust account (the “Trust Account”) of the Company, maintained by U.S. Bank, N.A. as the trustee for the benefit of the public shareholders of the Company, to allow the Company to extend its deadline for completing an initial business combination for 9 one-month extensions from July 28, 2023 to April 28, 2024; (y) 9 promissory notes, from April 2024 to December 2024, each issued to Mr. Chang in the amount of $60,000 (collectively, the “Second EGM Extension Notes”), pursuant to which Mr. Chang deposited $60,000 for each month to the Trust Account, to allow the Company to extend its deadline for completing an initial business combination for 9 one-month extensions from April 28, 2024 to January 28, 2025; and (z) 8 promissory notes, from January 2025 to August 2025, each issued to Mr. Chang in the amount of $55,824 (collectively, the “Third EGM Extension Notes,” and together with the First EGM Extension Notes and the Second EGM Extension Notes, the “Extension Notes”), pursuant to which Mr. Chang deposited $55, 824 for each month to the Trust Account, to allow the Company to extend its deadline for completing an initial business combination for 3 one-month extensions from January 28, 2025 to September 28, 2025.

Pursuant to the Merger Agreement and the Prospectus, up to $1,500,000 of the Working Capital Notes or Extension Notes may be converted into private placement units of the Company (the “Private Units”), each of which is the same as the private placement units sold in the private sales consummated simultaneously with the initial public offering of the Company, as described in the Prospectus.

As part of the transaction financing, on April 8, 2025, the Company, Pubco, Docter, and Mr. Chang, as the holder of the Working Capital Notes and the Extension Notes, entered into an exchange agreement (the “AIMA Exchange Agreement”), pursuant to which all $1,472,471 under the Extension Notes and $27,529 under the Working Capital Notes will be converted into 150,000 Private Units of the Company, and the remaining balance of the Working Capital Notes, including any working capital loans that may be provided prior to the closing of the Business Combination, less $27,529 will be exchanged for such number of PubCo ordinary shares, par value $0.0001 per share (“PubCo ordinary shares”), at a conversion price of $10.00 per share. The Private Units are issued pursuant to the exemption from registration under Section 4(a)(2) of the Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”).

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4. MINE SAFETY DISCLOSURES.

Not applicable.

ITEM 5. OTHER INFORMATION.

None.

32

ITEM 6. EXHIBITS

The following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.

Exhibit No.		Description
31.1*		Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*		Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1**		Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes- Oxley Act of 2002
32.2**		Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes- Oxley Act of 2002
101.INS*		Inline XBRL Instance Document
101.CAL*		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.SCH*		Inline XBRL Taxonomy Extension Schema Document
101.DEF*		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*		Inline XBRL Taxonomy Extension Labels Linkbase Document
101.PRE*		Inline XBRL Taxonomy Extension Presentation Linkbase Document
104*		Cover Page Interactive Data File (embedded within the Inline XBRL document)

* Filed herewith

** Furnished.

33

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Aimfinity Investment Corp. I
Date: October 17, 2025	By:	/s/ I-Fa Chang
		I-Fa Chang
		Chief Executive Officer
		(Principal Executive Officer)
Date: October 17, 2025	By:	/s/ Xuedong (Tony) Tian
		Xuedong (Tony) Tian
		Chief Financial Officer
		(Principal Financial and Accounting Officer)

34

NONE NONE NONE http://fasb.org/srt/2025#ChiefExecutiveOfficerMember 0001903464 false Q2 --12-31 0001903464 2025-01-01 2025-06-30 0001903464 aimau:UnitsConsistingOfOneNewUnitAndOneClass1RedeemableWarrantEachExercisableForOneClassAOrdinaryShareAtAnExercisePriceOf1150Member 2025-01-01 2025-06-30 0001903464 aimau:NewUnitsConsistingOfOneClassAOrdinaryShareAndOnehalfOfOneClass2RedeemableWarrantEachFullExercisableForOneClassAOrdinaryShareAtAnExercisePriceOf1150Member 2025-01-01 2025-06-30 0001903464 aimau:Class1RedeemableWarrantsEachExercisableForOneClassAOrdinaryShareAtAnExercisePriceOf1150Member 2025-01-01 2025-06-30 0001903464 us-gaap:CommonClassAMember 2025-10-17 0001903464 us-gaap:CommonClassBMember 2025-10-17 0001903464 2025-06-30 0001903464 2024-12-31 0001903464 us-gaap:RelatedPartyMember 2025-06-30 0001903464 us-gaap:RelatedPartyMember 2024-12-31 0001903464 us-gaap:CommonClassAMember 2025-06-30 0001903464 us-gaap:CommonClassAMember 2024-12-31 0001903464 us-gaap:CommonClassBMember 2025-06-30 0001903464 us-gaap:CommonClassBMember 2024-12-31 0001903464 2025-04-01 2025-06-30 0001903464 2024-04-01 2024-06-30 0001903464 2024-01-01 2024-06-30 0001903464 aimau:OrdinarySharesSubjectToRedemptionMember 2025-04-01 2025-06-30 0001903464 aimau:OrdinarySharesSubjectToRedemptionMember 2024-04-01 2024-06-30 0001903464 aimau:OrdinarySharesSubjectToRedemptionMember 2025-01-01 2025-06-30 0001903464 aimau:OrdinarySharesSubjectToRedemptionMember 2024-01-01 2024-06-30 0001903464 us-gaap:PreferredStockMember 2024-12-31 0001903464 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2024-12-31 0001903464 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2024-12-31 0001903464 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001903464 us-gaap:RetainedEarningsMember 2024-12-31 0001903464 us-gaap:PreferredStockMember 2025-01-01 2025-03-31 0001903464 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001903464 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001903464 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001903464 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001903464 2025-01-01 2025-03-31 0001903464 us-gaap:PreferredStockMember 2025-03-31 0001903464 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2025-03-31 0001903464 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2025-03-31 0001903464 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001903464 us-gaap:RetainedEarningsMember 2025-03-31 0001903464 2025-03-31 0001903464 us-gaap:PreferredStockMember 2025-04-01 2025-06-30 0001903464 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001903464 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001903464 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001903464 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001903464 us-gaap:PreferredStockMember 2025-06-30 0001903464 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2025-06-30 0001903464 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2025-06-30 0001903464 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001903464 us-gaap:RetainedEarningsMember 2025-06-30 0001903464 us-gaap:PreferredStockMember 2023-12-31 0001903464 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-12-31 0001903464 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2023-12-31 0001903464 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001903464 us-gaap:RetainedEarningsMember 2023-12-31 0001903464 2023-12-31 0001903464 us-gaap:PreferredStockMember 2024-01-01 2024-03-31 0001903464 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001903464 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001903464 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001903464 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001903464 2024-01-01 2024-03-31 0001903464 us-gaap:PreferredStockMember 2024-03-31 0001903464 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2024-03-31 0001903464 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2024-03-31 0001903464 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001903464 us-gaap:RetainedEarningsMember 2024-03-31 0001903464 2024-03-31 0001903464 us-gaap:PreferredStockMember 2024-04-01 2024-06-30 0001903464 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001903464 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001903464 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001903464 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001903464 us-gaap:PreferredStockMember 2024-06-30 0001903464 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2024-06-30 0001903464 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2024-06-30 0001903464 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001903464 us-gaap:RetainedEarningsMember 2024-06-30 0001903464 2024-06-30 0001903464 us-gaap:IPOMember 2022-04-28 2022-04-28 0001903464 us-gaap:OverAllotmentOptionMember 2022-04-28 2022-04-28 0001903464 us-gaap:CommonClassAMember us-gaap:IPOMember 2022-04-28 0001903464 us-gaap:IPOMember 2022-04-28 0001903464 us-gaap:CommonClassAMember 2022-04-28 2022-04-28 0001903464 aimau:PrivatePlacementUnitsMember 2025-01-01 2025-06-30 0001903464 aimau:PrivatePlacementUnitsMember 2025-06-30 0001903464 2022-04-28 2022-04-28 0001903464 2022-04-28 0001903464 aimau:PostTransactionCompanyMember 2025-06-30 0001903464 2024-04-28 0001903464 aimau:PublicShareholdersMember 2024-04-28 0001903464 2024-04-23 0001903464 2024-04-23 2024-04-23 0001903464 2024-05-23 0001903464 srt:ScenarioForecastMember 2025-10-28 0001903464 aimau:AimfinityInvestmentCorpMember us-gaap:CommonClassAMember 2025-01-01 2025-06-30 0001903464 us-gaap:CommonClassBMember us-gaap:IPOMember 2025-06-30 0001903464 aimau:SponsorMember 2025-06-30 0001903464 us-gaap:IPOMember 2025-06-30 0001903464 srt:ScenarioForecastMember 2025-12-31 0001903464 srt:ScenarioForecastMember 2026-12-31 0001903464 us-gaap:CommonStockMember 2025-06-30 0001903464 us-gaap:CommonStockMember 2024-12-31 0001903464 aimau:RedeemableCommonStockMember 2025-04-01 2025-06-30 0001903464 aimau:NonRedeemableCommonStockMember 2025-04-01 2025-06-30 0001903464 aimau:RedeemableCommonStockMember 2024-04-01 2024-06-30 0001903464 aimau:NonRedeemableCommonStockMember 2024-04-01 2024-06-30 0001903464 aimau:RedeemableCommonStockMember 2025-01-01 2025-06-30 0001903464 aimau:NonRedeemableCommonStockMember 2025-01-01 2025-06-30 0001903464 aimau:RedeemableCommonStockMember 2024-01-01 2024-06-30 0001903464 aimau:NonRedeemableCommonStockMember 2024-01-01 2024-06-30 0001903464 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasurySecuritiesMember 2025-06-30 0001903464 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasurySecuritiesMember 2024-12-31 0001903464 us-gaap:WarrantMember 2025-06-30 0001903464 us-gaap:IPOMember 2025-01-01 2025-06-30 0001903464 us-gaap:CommonClassAMember us-gaap:IPOMember 2025-01-01 2025-06-30 0001903464 us-gaap:CommonStockMember 2023-12-31 0001903464 us-gaap:CommonStockMember 2024-01-01 2024-12-31 0001903464 us-gaap:CommonStockMember 2024-12-31 0001903464 us-gaap:CommonStockMember 2025-01-01 2025-06-30 0001903464 us-gaap:CommonStockMember 2025-06-30 0001903464 aimau:AimfinityInvestmentLLCMember aimau:PrivatePlacementUnitsMember 2025-01-01 2025-06-30 0001903464 us-gaap:PrivatePlacementMember 2025-01-01 2025-06-30 0001903464 aimau:SponsorMember 2021-12-04 2021-12-04 0001903464 aimau:SponsorMember 2021-12-04 0001903464 us-gaap:CommonClassBMember 2022-03-18 2022-03-18 0001903464 aimau:FounderShares1Member us-gaap:CommonClassBMember 2022-03-18 0001903464 us-gaap:CommonClassBMember 2022-03-18 0001903464 aimau:FounderShares1Member 2025-06-30 0001903464 aimau:FounderShares1Member 2024-12-31 0001903464 srt:ChiefFinancialOfficerMember 2022-03-29 2022-03-29 0001903464 2022-03-29 2022-03-29 0001903464 aimau:PublicShareholdersMember 2025-06-30 0001903464 aimau:PublicShareholdersMember 2024-12-31 0001903464 aimau:PublicShareholdersMember 2025-04-30 0001903464 aimau:PromissoryNoteMember 2025-06-30 0001903464 aimau:DocterIncMember aimau:ExtensionLoansRelatedPartyMember 2025-04-08 0001903464 aimau:DocterIncMember aimau:ExtensionRelatedLoansMember aimau:ExtensionLoansRelatedPartyMember 2025-04-08 0001903464 aimau:DocterIncMember aimau:WorkingCapitalLoansMember aimau:ExtensionLoansRelatedPartyMember 2025-04-08 0001903464 aimau:PrivateUnitsMember 2025-04-08 0001903464 2021-01-01 2021-12-31 0001903464 2022-01-01 2022-12-31 0001903464 aimau:SponsorMember 2023-01-01 2023-12-31 0001903464 aimau:SponsorMember 2024-12-31 0001903464 2023-12-08 0001903464 2024-04-04 0001903464 aimau:SponsorMember 2023-12-08 0001903464 2024-10-21 0001903464 aimau:DocterIncMember 2025-04-08 0001903464 aimau:DocterIncMember aimau:ExtensionRelatedLoansMember 2025-04-08 0001903464 aimau:DocterIncMember aimau:WorkingCapitalLoansMember 2025-04-08 0001903464 srt:MinimumMember 2025-06-30 0001903464 srt:MinimumMember 2025-01-01 2025-06-30 0001903464 srt:MaximumMember 2025-06-30 0001903464 srt:MaximumMember 2025-01-01 2025-06-30 0001903464 2025-06-13 2025-06-13 0001903464 2025-06-13 0001903464 2025-04-08 2025-04-08 0001903464 us-gaap:CommonClassBMember aimau:SponsorMember 2021-12-04 0001903464 us-gaap:CommonClassBMember us-gaap:IPOMember 2022-03-18 2022-03-18 0001903464 us-gaap:WarrantMember us-gaap:CommonClassAMember 2025-06-30 0001903464 aimau:Class1WarrantsMember 2025-06-30 0001903464 aimau:Class2WarrantsMember 2025-06-30 0001903464 aimau:Class1WarrantsMember us-gaap:PrivatePlacementMember 2025-06-30 0001903464 aimau:Class2WarrantsMember us-gaap:PrivatePlacementMember 2025-06-30 0001903464 aimau:Class1WarrantsMember 2024-12-31 0001903464 aimau:Class2WarrantsMember 2024-12-31 0001903464 aimau:Class1WarrantsMember us-gaap:PrivatePlacementMember 2024-12-31 0001903464 aimau:Class2WarrantsMember us-gaap:PrivatePlacementMember 2024-12-31 0001903464 us-gaap:CommonClassAMember 2025-01-01 2025-06-30 0001903464 us-gaap:WarrantMember 2025-01-01 2025-06-30 0001903464 us-gaap:WarrantMember us-gaap:CommonClassAMember 2025-01-01 2025-06-30 0001903464 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember us-gaap:CommonClassAMember 2025-06-30 0001903464 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2025-01-01 2025-06-30 0001903464 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2025-06-30 0001903464 aimau:ChiefOperatingDecisionMakerMember 2025-04-01 2025-06-30 0001903464 aimau:ChiefOperatingDecisionMakerMember 2024-04-01 2024-06-30 0001903464 aimau:ChiefOperatingDecisionMakerMember 2025-01-01 2025-06-30 0001903464 aimau:ChiefOperatingDecisionMakerMember 2024-01-01 2024-06-30 0001903464 aimau:InkrockHoldingLimitedMember 2025-05-27 0001903464 aimau:IFaChangMember 2025-05-27 2025-05-27 0001903464 2025-05-27 2025-05-27 0001903464 us-gaap:SubsequentEventMember 2025-07-25 0001903464 us-gaap:SubsequentEventMember 2025-07-25 2025-07-25 0001903464 aimau:HornPIPEInvestorsMember us-gaap:SubsequentEventMember 2025-07-25 2025-07-25 0001903464 srt:ScenarioForecastMember 2025-10-06 2025-10-06 0001903464 aimau:PubCoMember srt:ScenarioForecastMember 2025-10-06 0001903464 srt:ScenarioForecastMember us-gaap:CommonStockMember 2025-07-25 2025-10-06 0001903464 srt:ScenarioForecastMember aimau:PublicShareholdersMember 2025-09-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure

FAQ

What was Aimfinity (AIMTF) net income for the six months ended June 30, 2025?

Net income was $75,425, reflecting $484,941 of trust interest and $409,516 of formation and operating costs.

How much cash and investments were in Aimfinity’s trust as of June 30, 2025?

The trust held $13,981,534 in money market funds investing in U.S. Treasury securities.

How many shares did Aimfinity redeem in 2025 and for what amount?

It redeemed 1,996,522 Class A shares for a total of $23,778,577.

What is the status of Aimfinity’s business combination timeline?

Extensions funded by deposits moved the deadline to October 28, 2025 to complete the business combination with Docter Inc.

Did Aimfinity convert any sponsor loans into equity in 2025?

Yes. On April 8, 2025, $1,500,000 of promissory notes were converted into 150,000 private units.

How were the deferred underwriting fees modified?

On June 13, 2025, each underwriter agreed to accept $80,000 cash and 132,875 PubCo shares at closing instead of the $2,817,500 deferred commission.

What are the redeemable shares as of June 30, 2025?

1,116,476 ordinary shares were classified as redeemable at a redemption value of $12.52 per share.